ç¥çµåçéºäŒå æè¡åé
æ¬çºæã¯ãã¢ãããŒã·ã¹ãèªå°ãã掻æ§ãç¥çµçŽ°èã®ååãããã³ç¥çµçŽ°èã®å¢ æ®ã®æŽ»ÂŸãæããã¢ãããŒã·ã¹é¢é£å åã 該å åãã³ãŒãããããªãã¯ã¬ãªããã 該ããªãã¯ã¬ãªãããçšãã該å åã®è£œé æ¹æ³ããããã®è£œé ã«é¢ããçºçŸç³»ã該 çºçŸç³»ãçšããã¢ãããŒã·ã¹ãèªå°ãã掻æ§ãç¥çµçŽ°èã®ååãããã³ç¥çµçŽ°èã® å¢æ®ã®æŽ»æ§ã®æ€åºæ¹æ³ããŸãã¯è©²æŽ»æ§ãå¶åŸ¡ããååç©ã®è©äŸ¡æ¹æ³ã䞊ã³ã«ã該㡠ãããŒã·ã¹é¢é£å åããŸãã¯è©²å åãã³ãŒãããããªãã¯ã¬ãªãããæå¹æåãšã ã现èå¢æ®ããŸãã¯çŽ°èæ»ã«ç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã«é¢ããã ãŸããæ¬çºæ ã¯æ¬çºæã®ã¢ãããŒã·ã¹é¢é£å åãèªèããæäœã該æäœãçšãã該å åã®å
ç«åŠ ç枬å®æ³ã«é¢ãã ããã«ã äžèšè©äŸ¡æ¹æ³ã«ããåŸãããååç©ãçšãã现èå¢æ®ã ãŸãã¯çŽ°èæ»ã«ç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã«é¢ããã èæ¯æè¡
ã¢ãããŒã·ã¹ããŸãã¯ããã°ã©ã 现èæ»ãšã¯çççæ¡ä»¶äžã§çŽ°èèªããåŒãèµ·ã ã现èã®æ»ã§ãããå€çŽ°èçç©ã®çåã«ãããŠã¯ãæãŸãããªãã ãããã¯å¿
èŠã® ç¡ã现èãçäœããæé€ããæ©æ§ãå¿
èŠã§ãããã¢ãããŒã·ã¹ã¯ãçºçéçšã现è ã®äžä»£äº€ä»£ã«ãããŠãäžèŠãšãªã£ã现èãæé€ããããã®äºããããã©ã ããã现 èã®æ»ã§ãããšç解ãããŠãããã¢ãããŒã·ã¹ãèµ·ããã现èã§ã¯ãæ žã®åçž®ã DNA ã®æçåã芳å¯ãããèãæ®ãããŸãŸçŽ°èãéçž®ããã çäœäžã§ã¯ããããŠéçž®ã ã现èãé£é£çŽ°èãæé£ãæé€ãããã¢ããäžã·ã¹ã«å¯ŸããŠãå£æ»ãšåŒã°ãã现è æ»ã¯çŽ°èæ§é ã®ç Žå£ã䌎ãããããã£ãŠã现èãèªãæ»æ»
ããŠããã¢ãããŒã·ã¹ã¯ã ãã°ãã°ã ãããããªçŽ°èæ»ã ãšåŒã°ããã
ãã®åŸãçºçéçšã§èŠ³å¯ããã现èæ»ãšåæ§ã®çŽ°èæ»å 现èã®å€ããåºæ¿ã«ã ã€ãŠãèªå°ãããŠããããšãç¥ãããããã«ãªã£ããäŸãã°ã TNFã Fasã¯ã ã¢ãã âã·ã¹ãèªå°ãã代衚çãªãµã€ãã«ã€ã³ã§ããã ãŸãã玫å€ç·ãŸ1^ç·ç
§å°ã现è å¢æ®å åã®æ¯æžŽãããçš®ã®çéºäŒåã®æŽ»æ§ã£åãšãã£ãåºæ¿ã«ãã£ãŠããã¢ãããŒã· ã¹ã¯èªå°ãããã èªå·±å
ç«çŸæ£ãçã®ãããªçŸæ£ããã¢ãããŒã·ã¹ã®æ©èœäžå
šã«ã ã€ãŠã æ害ãªçŽ°èãæ»æ»
ãããããªãã€ãçµæãšããŠç解ãããããã«ãªã£ãã çŸåšã®ãšããã现èãå€çããã®åºæ¿ã«å¿çããŠã¢ãããŒã·ã¹ã«è³ãéçšã¯ãã ãã次ã®ããã«èª¬æãããŠããã å³ã¡ã æ§ã
ãªåå ã«ãã£ãŠæŽ»æ§ã£åããã Caspase ãã¡ããªãŒã现èæ»ãããããããšãæããã«ãããŠããã Caspaseã«ã¯åºè³ªç¹ç° æ§ã®ç°ãªãè€æ°ã®é
µçŽ ã®ååšãæããã«ãããŠããã äžçŸ€ã® Caspaseãç·ç§°ã㊠Caspaseãã¡ããªãŒãšåŒãã§ããã Caspaseãã¡ããªäžã¯ãåºè³ªç¹ç°æ§ã«ãã£ãŠå€§ã ã 3ã€ã®ã°ã«ãŒãã«åé¡ãããŠããã ãã®ãã¡ã ã°ã«ãŒã 2ã® Caspaseãã ã¢ãã äžã·ã¹ã®å®è¡ã«é¢äžãããšèšãããŠããã ã°ã«ãŒã 3ã® Caspaseã¯ã ã¢ãããŒã·ã¹ å®è¡ã«ã¹ã±ãŒãã®äžæµã«ãããŠã现èå€ããã®åºæ¿ã«å¿çããŠæŽ»æ§åããã ããäž æµã®ã°ã«ãŒã 2ã® Caspaseã掻æ§ã£åããåããæã€ã äžæ¹ã°ã«ãŒã 1ã® Caspaseã¯ã ãµã€ãã«ã€ã³ã®çæãšåæ³ãä¿é²ããäœçšãæã€ãšãããŠãããã°ã«ãŒã 2ãšãã« ãŒã 3ã«åé¡ããã Caspaseãšã ãããèªèããã¢ããé
žé
åã以äžã«ç€ºãã
ã°ã«ãŒã 2 ã°ã«ãŒã 3
Caspaseâ 2 DEHD Caspase- 6 VEHD
Caspase- 3 DEVD Caspase- 8 LETD
Caspase- 7 DEVD Caspase- 9 LETD
ã°ã«ãŒã 3ã® Caspaseã¯ã Fasã TNFã¬ã»ãã¿ãŒã«ãªã¬ã³ããçµåããããšã«ãã 掻æ§åããã ã°ã«ãŒã 2ã® CaspaseãåæããŠæŽ»æ§åãã ããäžæµã«ã·ã°ãã«ãäŒ éããã ãã®ãããªã·ã°ãã«ã®äŒéãã¢ãããŒã·ã¹å®è¡åã¹ã±ãŒããšåŒã¶ã ã¡ãã äžã·ã¹å®è¡ã«ã¹ã±ãŒãã®äžæµã§ã¯ãã·ã°ãã«ãäŒéãããæ§ã
ãªå åãã现èæ»ã ããããããã®å®è¡éšéãšããŠæ©èœããŠããããšãæšæž¬ãããã
ãå ããå®éã«ã©ã®ãããªå åã现èã®æ»ããããããŠããã®ãã«ã€ããŠã¯ã解 æãã¹ã課é¡ãå€ãã ããšãã°ã ãã皮㮠Caspaseã¯ãã¯ã¬ã¢ãŒãŒé»å®³å å
ICAD (inhibitor of CAD)ãå解ããã ãã®çµæã ãã¯ã¬ã¢ãŒãŒã§ãã CAD(Caspase Activated DNase)ã®æ žãžã®ç§»è¡ãå¯èœãšãªãã ã¢ããäžã·ã¹ã«ç¹åŸŽçãªæè²äœ DNA ã®åæãéå§ããããšãç¥ãããŠããïŒEnari M, et al. , Nature, 391 :43 - 50, 1998)ã ã¢ãããŒã·ã¹ã¯ç¥çµç³»ã®çºéã«ãããŠãéèŠãªéçšã§ãã ïŒJohnson EM and Deckworth, Ann. Rev. Neurosci. , 16ïŒ 31 - 46 (1993) ïŒ Oppenheim RW, Annu. Rev. Neurosci. , 14ïŒ 453-501 (1991) ïŒ Raff MC et al. , Science 262ïŒ 695-700 (1993) ) ã ã¢ãããŒã·ã¹ã¯ç©ççãããŽç°å¢çã·ã°ãã«ã«ããå³å¯ã«èª¿ç¯ãããŠãããã£ã³ã· ãŠãªã³æ§æé·å å I (IGF- 1)çã®æé·å åã«ããã¢ãããŒã·ã¹ã¯é»å®³ãããããã« ããæ£åžžããã³ç°åžžãªç¥çµçŽ°èã®çåã䞊ã³ã«ãå¢æ®ã調ç¯ããã ïŒDïŒ Mello SR et al.ïŒ J. Neurosci. 17ïŒ 1548-1560 (1997) ïŒ Rukenstein A et al. , J. Neurosci. 11ïŒ 2552-2563 (1991) ïŒ Sc lessinger J et al. , Neuron 9ïŒ 383-391 (1992) ïŒ Yao R and Cooper GMïŒ Science 267ïŒ 2003-2006 (1995) ) ã
ã¢ãããŒã·ã¹éå§æã®äžå
šã¯ãäžæ¢ãããŽæ«æ¢¢ç¥çµç³»ã«ãããè
«çåã®éèŠãªæ© æ§ã®äž"1 ã§ãã (Fung K- and Trojanwski JQ, J. Neuropathol. Exp. Neurol. 54ïŒ 285-297 (1995)ïŒ Yachnis AT et al. , J. Neuropathol. Exp. Neurol. 53ïŒ 61-71 (1994) ) 0 ç¥çµå€æ§çŸæ£ ïŒWhite EïŒ Genes Dev. , 10ïŒ 1-15 (1996) ïŒ Friedlander RM and Yuan J, Cell Death and Differentiation 5ïŒ 823-831 (1998) ïŒ Jacobson MD, Curr. Biol. 8ïŒ R418-R421 (1998)ïŒ Tatton WG et al. , J. Neural Transmission, Suppl. 49: 245-268 (1997) ) ãããŽèè¡æ§çŸæ£ ïŒChoi DW and Rothman SM.ïŒ Annu. Rev. Neurosci. , 13ïŒ 171-182 (1990) ) ã«ãããŠèµ·ããç¥çµçŽ°èæ»ã«ãã¢ãããŒã·ã¹ã¯é¢é£ããŠãããšè ããããŠããã
ç¥çµçŽ°èã®ã¢ãããŒã·ã¹ã«é¢é£ããéºäŒåãšããŠã¯ã AATYK (Apoptosis
Associated Tyrosine Kinase) ãšåŒã°ããããŠã¹ã®éºäŒåãèé«åé§çŽ°èããåå® ãããŠãã (Gaozza E. et al.ïŒ Oncogene, 15ïŒ 3127â3135 (1997) ) ã MTYKéºäŒ
åã«ããã³ãŒãããã 200kDaã®èçœè³ªã¯ Næ«ç«¯ã«ããã·ã³ãããŒãŒãã¡ã€ã³ãæãã Cæ«ç«¯ã«ãããªã³ã«å¯ã¿ã æå° SH3çµåã¢ããŒããæ§æãã 16 PXXPã¢ããŒããæã ãŠããã è¡ç现èã®ãµã€ãåã€ã³é€å»ã«ããã¢ãããŒã·ã¹æã«ã MTYKã®çºçŸã匷 ãèªå°ãããããšãå ±åãããŠããã
MTYKéºäŒåã®çºçŸã¯ã èé«åé§çŽ°èã®çè²æå¶ãã㎠ZãŸãã¯ã¢ãããŒã·ã¹ã® èªå°ã«äžå¯æ¬ ãšèããããŠããã MTYKèçœè³ªã¯è³ã§ç¹ã«å€ãçºçŸãããŠããã ç¥ çµåã£åã«äŒŽãçºçŸã¯å¢å ããããšãç¥ãããŠãã ïŒBaker SJ et al.ïŒ Oncogene, 20: 1015-1021 (2001) ïŒ Tomura M et al. , Oncogene, 20ïŒ 1022-1032 (2001) ) ã ãŸãã MTYKã¯æ žèè¿ãã®çŽ°è質äžã«ååšããé
µçŽ çã«æŽ»æ§ãªéå容äœãããŒãŒã§ããã éå°çºçŸã«ããã¡ãã¬ããªã³äœåæ§ç¥çµèœè
« SH-SY5Y现èçã®çŽ°èã®åã£ããèªå°ãã ãããŠã ã¬ããã€ã³é
ž (RA)ã 12 - 0"ããã©ãã«ãã£ã«ãã«ããŒã« 13 -ã¡ã»ã¿ãŒãã ããã³ IGF - 1çã«ããèªå°ãããç¥çµçŽ°èååãä¿é²ããããšãç¥ãããŠãã
(Raghunath M et al.ïŒ Molecular Brain Res. 77ïŒ 151-162 (2000) ) ã
ãã®ããã«ãã¢ãããŒã·ã¹å®è¡ã«ã¹ã±ãŒããæ§æããå åã«ã¯ãã¢ãããŒã·ã¹ã® å®è¡ãããã³ç¥çµç³»ã®çºé Zåã£åã«ãããŠéèŠãªåããæã€ååãå€ãååšãããš èããããã ãããã®å åã¯ã ã¢ãããŒã·ã¹ã®å¶åŸ¡ãããã³ç¥çµç³»ã®çºé Zååã« ãããŠéèŠãªæšçãšãªãå¯èœæ§ãããã
ãŸãæè¿ã§ã¯ã ç¥çµçŽ°èã®æã¢ãããŒã·ã¹æŽ»æ§ãšã ãµã€ã¯ãªã㯠AMP (cAMP)å¿ç é
åïŒCRE;cAMP responsive element)ã«çµåãã転åå åïŒCREB ïŒ cAMP responsive element binding protein)ã®æŽ»æ§äžæãšã®çµã³ã€ãã瀺åãããŠããã CREBã¯ã cAMP äŸåæ§ãããã£ã³ãããŒãŒã«ãã Serl33ããªã³é
žåãã掻æ§ã£åããã
ãã®ä»ãã¡ã¡ãã©ã·ãã©ããã®è¡åèšæ¶ã«ã€ããŠã®å®éšçµæããã CREBã®ãªã³é
ž åãèšæ¶åœ¢æã«ãããŠéèŠã§ããããšãç¥ãããŠãã ïŒSilvia AJ et al. , Annu. Rev. Neurosci. 21ïŒ 127 (1998) ) ã ãŸãã ã¢ã«ããã€ããŒåçŽåã§ã¯ã è³å
ã®ãª ã³é
žå CREBã®éãææã«æžå°ããŠããïŒYamamoto- Sasaki M et al.ïŒ Brain Res. 824ïŒ 300-303 (1999) ) ã 以äžã®ããšãã CREB掻æ§ã®äžæãèšæ¶åœ¢æãšé¢é£ããããšã瀺
åãããŠããã CREBã®è»¢å掻æ§ã®äžæãéããŠèšæ¶ ·ç¥çµå€æ§ãæ¹åããå¹
åºãç¥ çµçŸæ£ã«å¯Ÿããæ²»çå¹æãæåŸ
ã§ããã çºæã®é瀺
æ¬çºæã®èª²é¡ã¯ãã¢ãããŒã·ã¹ããããã¯ç¥çµçŽ°èã®ååãå¢æ®ã«é¢äžããéºäŒ åãåå®ããããšã§ããããŸãæ¬çºæã¯ããã®ãããªæ©èœãæããéºäŒåãçšããã ã¢ãããŒã·ã¹ãèªå°ãã掻æ§ããããã¯ç¥çµçŽ°èã®åã£ããå¢æ®ãèªå°ãã掻æ§ã調 ç¯ããååç©ã®è©äŸ¡æ¹æ³ã® ã課é¡ãšããã ãããã®éºäŒåãã®ãã®ãããã㯠ãããã®æŽ»æ§ãå¶åŸ¡ããååç©ã¯ãç¥çµçŽ°èã®å¢æ®ããŸãã¯çŽ°èæ»ã«é¢é£ããçŸæ£ ã«å¯Ÿããæ²»çå¹æãæåŸ
ã§ããã
æ¬çºæè
ãã¯ã ããŠã¹ MTYKã®ãããŒãŒãã¡ã€ã³ãšæ§é çã«é¡äŒŒããã¢ããŒãã æãã 2ã€ã®èçœè³ªãåå®ãããäž¡è
ã®ã¢ããé
žé
åã«ã¯å
±éããé åãèŠåºããã ãªã«ã¿ããã£ãã¹ãã©ã€ã·ã³ãããªãŒã ã§ãããšèããããããããã®èçœè³ªã®ã ã¡ãäžæ¹ã¯æ¬çºæè
ãã«ãã€ãŠèŠåºãããæ°èŠãªã¡ããé
žé
åãããªãèçœè³ªã§ã ã€ããä»æ¹ã¯ãæ¢ã«æ§é ãæããã«ãããŠããéºäŒåã«ãã£ãŠã³ãŒããããŠããå ãã®æ©èœã¯æããã«ãããŠããªãã
次ã«æ¬çºæè
ãã¯ããããã®èçœè³ªãã¢ãããŒã·ã¹èªå°æŽ»æ§ãæããããšãç¢ºèª ããããŸãæ¬çºæè
ãã¯ããããèçœè³ªã®ç¥çµçŽ°èãžã®äœçšã解æããããã®çµæã ãããã®èçœè³ªããã¢ãããŒã·ã¹èªå°äœçšã«å ããŠãç¥çµçŽ°èã®ååãå¢æ®ã匷å ã«èªå°ããããšãæããããšãèŠåºãããæŽã« AF06972ã¯ãè³ã«ãããçºçŸãé«ãã ç¥çµçŽ°èãšã®å¯æ¥ãªé¢é£æ§ã瀺ãããã
ãããã®ç¥èŠã«åºã¥ããŠãåèšèçœè³ªããããã¯ãããã³ãŒãããéºäŒåãçšã ãŠãåè£ç©è³ªã®ã ã¢ãããŒã·ã¹èªå°æŽ»æ§ã ãããã¯ç¥çµçŽ°èã®åã£ããå¢æ®ãèªå°ã ã掻æ§ã調ç¯ããäœçšãæ€åºãããããšãæããã«ããæ¬çºæãå®æãããæŽã«æ¬ çºæè
ãã¯ã ãã®æ€åºæ¹æ³ã«åºã¥ããŠãã¢ãããŒã·ã¹èªå°æŽ»æ§ã ãããã¯ç¥çµçŽ°è ã®ååãå¢æ®ãèªå°ãã掻æ§ã調ç¯ããäœçšãæããååç©ã®è©äŸ¡æ¹æ³ã確ç«ã
ãã
ããªãã¡æ¬çºæã¯ã以äžã®ããªãã¯ã¬ãªããããã®ããªãã¯ã¬ãªããã«ãã£ãŠã³ ãŒããããèçœè³ªã«é¢ããã ãŸãæ¬çºæã¯ãåèšããªãã¯ã¬ãªããã ãããã¯åèš èçœè³ªã®ã æ€åºæ¹æ³ãçšéã«é¢ããã
æŽã«æ¬çºæã¯ãã¢ãããŒã·ã¹èªå°æŽ»æ§ããããã¯ç¥çµèŸèååå¢æ®æŽ»æ§ãæãã èçœè³ªãçšããã ãããã®æŽ»æ§ã調ç¯ãã掻æ§ã®æ€åºæ¹æ³ã«é¢ãããå ããŠæ¬çºæ ã¯ãåèšæ€åºæ¹æ³ã«åºã¥ãã ãããã®æŽ»æ§ã調ç¯ãã掻æ§ãæããååç©ã®è©äŸ¡æ¹ æ³ã«é¢ããããŸãæ¬çºæã¯ãåèšè©äŸ¡æ¹æ³ã«ãã£ãŠåŸãããšãã§ããååç©ã®çšé ã«é¢ããã
ã1ã äžèš ïŒa ) ã ïŒe ) ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã
( a ) é
åçªå·ïŒ 3ã«èšèŒãããå¡©åºé
åãå«ãããªãã¯ã¬ãªããã
( b )é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãã³ãŒãããããªã㯠ã¬ãªããã
( c ) é
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åãå«ã¿ã ãã€é
åçªå·ïŒ 4ã«èšèŒã®ã¡ ããé
žé
åã«ãããŠã 1è¥ããã¯æ°åã®ã¢ããé
žã眮æãæ¬ å€±ãæ·å
¥ã ãã ㎠/ãŸãã¯ä»å ããã¢ããé
žé
åãããªããé
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
ž é
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããããªãã¯ã¬ãªã ããã
( d ) é
åçªå·ïŒ 5ã«èšèŒã®å¡©åºé
åãå«ã¿ãé
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åã ããªãããªãã¯ã¬ãªãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºãã é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ª ãã³ãŒãããããªãã¯ã¬ãªããã ããã³
( e )é
åçªå·ïŒ 5ã«èšèŒã®å¡©åºé
åããéžæãããå¡©åºé
åãå«ã¿ã ãã€é
å çªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãš 7 0 %以äžã®ãã¢ããžäžãæããé
åçªå·ïŒ 4 ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãã ãããªãã¯ã¬ãªããã
ã2ãé
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åããéžæãããã¢ããé
žé
åãã³ãŒãã ãããªãã¯ã¬ãªããã
ã3ã é
åçªå·ïŒ 5ããéžæãããå¡©åºé
åãå«ãããªãã¯ã¬ãªããã
ã4ã é
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åãå«ã¿ã ãã€é
åçªå·ïŒ 4ã«èšèŒã®ã¢ã ãé
žé
åã«ãããŠã 1è¥ããã¯æ°åã®ã¢ããé
žã眮æãæ¬ å€±ãæ·å
¥ã ããã³/ ãŸãã¯ä»å ããã¢ããé
žé
åãããªããé
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
žé
åã ããªãèçœè³ªã«å¯ŸããŠãããã³ããã¬ãã£ãã®åœ¢è³ªãæã€èçœè³ªãã³ãŒãã ãããªãã¯ã¬ãªããã
ã5ã ã1ïŒ] ã ã4ã ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒãããã èçœè³ªã
ã6ã ã1ã ã ã4ã ã®ããããã«èšèŒã®ããªãã¯ã¬ãªãããå«ããã¯ã¿ãŒã ã7ã ã1ã ã ã4ã ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã ãŸã㯠ã6ã ã«èšèŒ ã®ãã¯ã¿ãŒãä¿æãã圢質転æäœã
ã8ã ã7ãã«èšèŒã®åœ¢è³ªè»¢æäœãå¹é€ããçºçŸç£ç©ãååããå·¥çšãå«ãã ã5ã ã«èšèŒã®èçœè³ªã®è£œé æ¹æ³ã
ã 9ãé
åçªå·ïŒ 5ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ãªããããŸãã¯ãã®çžè£ éã«çžè£çãªå¡©åºé
åãããªãå°ãªããšã 1 5å¡©åºã®é·ããæããããªã㯠ã¬ãªããã
ã1 0ãé
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åã«ãã£ãŠæ§æãããæå決å®åºãèªè ããæäœã
ã1 1ã é
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åãå«ãèçœè³ªãèªèããæäœã
ã1 2ã ã5ã ã«èšèŒã®èçœè³ªãšã該èçœè³ªãèªèããæäœã®å
ç«åŠçãªåå¿ã芳 å¯ããå·¥çšãå«ãã ã5ã ã«èšèŒã®èçœè³ªã®å
ç«åŠç枬å®æ³ã
ã1 3ã 次ã®å·¥çšãå«ãã ã¢ãããŒã·ã¹ãå¶åŸ¡ãã掻æ§ãæ€åºããæ¹æ³ã
( 1 ) 次㮠ïŒa ) ã ( d ) ã®ããããã«èšèŒã®èçœè³ªãçºçŸãã现èã«äŸ¯è£ç©è³ª ãæ¥è§Šãããå·¥çšã
( a )é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
žé
åãããªãèçœè³ªã
(b)é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ ã©ãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããããªãã¯ã¬ãªã ãã«ãã£ãŠã³ãŒãããã ïŒa) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã
(c)é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ã ãã¯è€æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ãããã³/ãŸãã¯ä»å ããã¢ããé
ž é
åãæãã ïŒa) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã
(d)é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãš 90%以äžã®ã ã¢ããžäžãæããã¢ããé
žé
åãããªãã ïŒa)ã«èšèŒã®èçœè³ªãšæ©èœçã« åçãªèçœè³ª
(2)ã¢ãããŒã·ã¹ãèªå°ãããæ¡ä»¶äžã§åèšçŽ°èãå¹é€ããåèšçŽ°èã®ã¢ãã âã·ã¹ã枬å®ããå·¥çšã ããã³
(3) å·¥çš (2) ã®æž¬å®çµæãææšãšããŠã ã¢ãããŒã·ã¹ãæå¶ã ãŸãã¯ä¿é²ã ã掻æ§ãæ€åºããå·¥çš
ã14ã 次ã®å·¥çšãå«ãã ã¢ãããŒã·ã¹ãå¶åŸ¡ãã掻æ§ãæããç©è³ªã®è©äŸ¡æ¹æ³ã
(1) ã1 3ã ã«èšèŒã®æ¹æ³ã«ãã£ãŠåè£ç©è³ªã®ã¢ãããŒã·ã¹ãæå¶ã ãŸãã¯ä¿ é²ãã掻æ§ãæ€åºããå·¥çšã ããã³
(2)察ç
§ãšæ¯èŒããŠãåèšçŽ°èã®ã¢ãããŒã·ã¹ãæå¶ã ãŸãã¯ä¿é²ãã掻æ§ã æããåè£ç©è³ªãéžæããå·¥çš
ã1 5ã 次ã®å·¥çšãå«ãã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ããã³ç¥çµçŽ°èã®å¢æ® ã®ãããããå¶åŸ¡ãã掻æ§ãæ€åºããæ¹æ³ã
(1) åè£ç©è³ªã®ååšäžã é
åçªå·ïŒ 1ã ãŸãã¯ã é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãéºäŒåã®çºçŸå¶åŸ¡é åãšããã®äžæµã«æ©èœçã«çµåãããã¬ãäž ã¿ãŒéºäŒåãå«ããã¯ã¿ãŒãçºçŸãããå·¥çšã
(2) åèšã¬ããŒã¿ãŒéºäŒåã®æŽ»æ§ã枬å®ããå·¥çšã ããã³
(3) å·¥çš ïŒ2) ã®æž¬å®çµæãææšãšããŠã ã¢ãããŒã·ã¹ã ç¥çµçŽ°èã®ååã å
ãŽã ç¥çµçŽ°èã®å¢æ®ã®ãããããå¶åŸ¡ãã掻æ§ãæ€åºããå·¥çšã
ã1 6ã 次ã®å·¥çšãå«ãã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ããã³ç¥çµçŽ°èã®å¢æ® ã®ãããããå¶åŸ¡ãã掻æ§ãæããç©è³ªãè©äŸ¡ããæ¹æ³ã
( 1 ) ã1 5ã ã«èšèŒã®æ¹æ³ã«ãã£ãŠãåè£ç©è³ªã®ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®å ã£åãããã³ç¥çµçŽ°èã®å¢æ®ã®ãããããæå¶ããŸãã¯ä¿é²ãã掻æ§ãæ€åºã ãå·¥çšã 䞊ã³ã«
(2) 察ç
§ãšæ¯èŒããŠã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ããã³ç¥çµçŽ°èã®å¢æ® ã®ãããããæå¶ã .ãŸãã¯ä¿é²ãã掻æ§ãæãã䟯è£ç©è³ªãéžæããå·¥çš
ã1 7ã次ã®å·¥çšãå«ããç¥çµçŽ°èã®åã£ãããã³/ãŸãã¯å¢æ®ãå¶åŸ¡ãã掻æ§ãæ€ åºããæ¹æ³ã
(1) 次㮠ïŒa)ãïŒd) ã®ããããã«èšèŒã®èçœè³ªãçºçŸããç¥çµçŽ°èã«åè£ ç©è³ªãæ¥è§Šãããå·¥çšã
(a)é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªã
(b)é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ ã©ãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããããªãã¯ã¬ãªã ãã«ãã£ãŠã³ãŒãããã ïŒa) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã
(c)é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ã ãã¯è€æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ãããã³/ãŸãã¯ä»å ããã¢ããé
ž é
åãæãã ïŒa) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã
(d)é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãš 90%以äžã®ã ã¢ããžäžãæããã¢ããé
žé
åãããªãã ïŒa) ã«èšèŒã®èçœè³ªãšæ©èœçã« åçãªèçœè³ª
(2)ç¥çµçªèµ·ã®äŒžå±ãèªå°ãããæ¡ä»¶äžã§åèšçŽ°èãå¹é€ããåèšçŽ°èã®ç¥çµ çªèµ·ã®äŒžå±ã枬å®ããå·¥çšã ããã³
(3) å·¥çšïŒ2) ã®æž¬å®çµæãææšãšããŠãç¥çµçŽ°èã®ååããã³/ãŸãã¯å¢æ® ãæå¶ã ãŸãã¯ä¿é²ãã掻æ§ãæ€åºããå·¥çš
- 1 o-
ã1 8ã次ã®å·¥çšãå«ããç¥çµçŽ°èã®åã£ãããã³ ZãŸãã¯å¢æ®ãå¶åŸ¡ãã掻æ§ãæ ããç©è³ªã®è©äŸ¡æ¹æ³ã
( 1 ) ã1 7ãã«èšèŒã®æ¹æ³ã«ãã£ãŠåè£ç©è³ªã®ç¥çµçŽ°èã®ååããã³ ZãŸã㯠å¢æ®ãå¶åŸ¡ãã掻æ§ãæ€åºããå·¥çšã 䞊ã³ã«
( 2 )察ç
§ãšæ¯èŒããŠãç¥çµçŽ°èã®ååããã³ ZãŸãã¯å¢æ®ãå¶åŸ¡ãã掻æ§ãæ ããåè£ç©è³ªãéžæããå·¥çš
ã1 9ã 现èå¢æ®ã ãŸãã¯çŽ°èæ»ã®å¶åŸ¡ã«ããã ã1 4ã ã ãŸã㯠ã1 6ã ã«èšèŒ ã®æ¹æ³ã«ãã£ãŠåŸãããšãã§ããååç©ã®äœ¿çšã
ã2 0ã ã1 4ã ã ãŸã㯠ã1 6ã ã«èšèŒã®æ¹æ³ã«ãã£ãŠåŸãããšãã§ããååç© ãäž»æåãšããŠå«æããããšãç¹åŸŽãšããã现èå¢æ®ããŸãã¯çŽ°èæ»ã«ç¹åŸŽä» ããããçŸæ£ã®æ²»çå€ã
ã2 1ãç¥çµçŽ°èã®ååãã㎠ZãŸãã¯å¢æ®ã®å¶åŸ¡ã«ãããã ã 1 6ãããŸãã¯ã 1
8ã ã«èšèŒã®æ¹æ³ã«ãã£ãŠåŸãããšãã§ããååç©ã®äœ¿çšã
ã2 2ã ã1 6ã ã ãŸã㯠ã1 8ã ã«èšèŒã®æ¹æ³ã«ãã£ãŠåŸãããšãã§ããååç© ãäž»æåãšããŠå«æããããšãç¹åŸŽãšãããç¥çµçŽ°èã®å¢æ®ããŸãã¯çŽ°èæ»ã« ç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã
ã2 3ã现èå¢æ®ã ãŸãã¯çŽ°èæ»ã®å¶åŸ¡ã«ããã ã5ãèšèŒã®èçœè³ªããŸãã¯ã1ã
ã ã4ã ã«èšèŒã®ããªãã¯ã¬ãªããã®äœ¿çšã
ã2 4ã äžèšã® ïŒa ) ã ïŒg ) ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã ãŸãã¯ãã® ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªãäž»æåãšããŠå«æããã现è å¢æ®ã 现èååã ãŸãã¯çŽ°èæ»ã«ãã€ãŠç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã
( a ) é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ ã©ãã
( b ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãã³ãŒãããã ãªãã¯ã¬ãªããã
( c ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ã
ãã¯è€æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ·å
¥ãããã²ã³ãŸãã¯ä»å ããã¢ããé
ž é
åãæãã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããã ãªãã¯ã¬ãªããã
( d ) é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ ã©ãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããé
åçªå·ïŒ 2ãé
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªã ã³äžãããããªãã¯ã¬ãªããã
( e ) é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãš 90%以äžã®ãã¢å£ ãžãŒãæããå¡©åºé
åãããªããé
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒ ã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããã㪠ãã¯ã¬ãªããã
( f ) ( a )ãïŒe ) ã«èšèŒã®ããªãã¯ã¬ãªããã®ã¢ã³ãã»ã³ã¹ããªãã¯ã¬ãªã ããã
( g ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãããŠã 1è¥ ããã¯æ°åã®ã¢ããé
žã眮æãæ¬ å€±ãæ·å
¥ãããã³ ZãŸãã¯ä»å ããã¡ãã é
žé
åãããªããé
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
å å ããªãèçœè³ªã«å¯ŸããŠãããã³ããã¬ãã£ãã®åœ¢è³ªãæã€èçœè³ªãã³äž ãããããªãã¯ã¬ãªããã
5ã以äžã®ïŒ a )ãïŒ d )ã®ããããã«èšèŒã®èçœè³ªã®çºçŸã調ç¯ãããã©ã³ã¹ãž ãšããã¯éããåç©ãããªããã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååãããã³ç¥çµçŽ° èã®å¢æ®ã調ç¯ãããã¢ãã«åç©ã
( a )é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ª
( b )é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªã DNAãšã¹ã㪠ã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºãã DNAã«ãã£ãŠã³ãŒããããïŒa )ã« èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ª
( c )é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ãã
ã¯è€æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ãããã³ ZãŸãã¯ä»å ããã¢ããé
žé
åãæãã ïŒa)ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ª
(d)é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãš 90%以äžã®ã ã¢ããžäžãæããã¢ããé
žé
åãããªããïŒ a )ã«èšèŒã®èçœè³ªãšæ©èœçã«å çãªèçœè³ª
ã26ãçäœè©Šæäžã®ã¢ãããŒã·ã¹ããŒã«ãŒã枬å®ãã該ã¢ãããŒã·ã¹ããŒã«ãŒã® 枬å®ã¬ãã«ã®äžæãåœè©²çäœè©Šæã«ãããã¢ãããŒã·ã¹ã瀺ãå·¥çšãå«ãã¡ ãããŒã·ã¹ã®æ€åºæ¹æ³ã§ãã£ãŠã ã¢ãããŒã·ã¹ããŒã«ãŒã次ã (a) äž (e) ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã ãŸã㯠ïŒa) â (e) ã®ããããã«èš èŒã®ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªã§ããæ¹æ³ã
(a) é
åçªå·ïŒ 3ã«èšèŒãããå¡©åºé
åãå«ãããªãã¯ã¬ãªããã
(b)é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãã³ãŒãããããªãã¯ã¬ ã©ããã
(c) é
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åãå«ã¿ã ãã€é
åçªå·ïŒ 4ã«èšèŒã®ã¢ã ãé
žé
åã«ãããŠã 1è¥ããã¯æ°åã®ã¢ããé
žã眮æãæ¬ å€±ãæ·å
¥ã ããã³ Z ãŸãã¯ä»å ããã¢ããé
žé
åãããªããé
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã ããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããããªãã¯ã¬ãªããã
(d) é
åçªå·ïŒ 5ã«èšèŒã®å¡©åºé
åãå«ã¿ã é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãã ãªãããªãã¯ã¬ãªãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããé
å çªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒ ãããããªãã¯ã¬ãªããã ããã³
(e)é
åçªå·ïŒ 5ã«èšèŒã®å¡©åºé
åããéžæãããå¡©åºé
åãå«ã¿ã ãã€é
åçª å·ïŒ 3ã«èšèŒã®å¡©åºé
åãš 70 %以äžã®ãã¢ããžäžãæããé
åçªå·ïŒ 4ã«èš èŒã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããã㪠ãã¯ã¬ãªããã
ã2 7ã 次ã®å·¥çšãå«ãã åçèçã®èšºææ¹æ³ã
( 1 ) ã2 6ã ã«èšèŒã®æ¹æ³ã«ãã£ãŠãè现èãçäœè©ŠæãšããŠã¢ãããŒã·ã¹ã æ€åºããå·¥çšã ããã³
( 2 ) å·¥çš ïŒ1 ) ã«ãããŠã¢ãããŒã·ã¹ãæ€åºãããå Žåã«ãåçèçãé²è¡ã ãŠãããšå€å®ããå·¥çš
æ¬çºæè
ãã¯ã æ¢ã«å¡©åºé
åãå ±åãããŠããããŠã¹ããã·ã³ãããŒãŒ MTYKéº äŒåã®æ
å ±ã«åºã¥ããŠãããã DNAç 究æã®ããè³çµç¹ç±æ¥ã® DNAããŒã¿ããŒã¹ãã ãã MTYKãšæããã次ã®ã¯ããŒã³ãèŠåºããã
HJ06941 (KIAA1078, GenBank Acc. No. AB029001)
æŽã«ã ãã®éºäŒåã®å¡©åºé
åæ
å ±ã䞊ã³ã«ç¿»èš³ã¢ããé
žé
åæ
å ±ãå©çšããŠãã å£ã·ã³ãããŒãŒãã¡ã€ã³ã«ãããŠã 4 1 %ã®çžåæ§ã瀺ã次ã®ã¯ããŒã³ãèŠåºãã ãšã«æåããã
HJ06972 (KIM1079ã GenBank Acc. No. AB029002)
ãã MTYKéºäŒåã«ããã³ãŒããããããã·ã³ãããŒãŒã¯ã 1317æ®åºã®ã¢ããé
ž ã«ããæ§æãããŠããã®ã«å¯Ÿãã HJ06972éºäŒåã«ããã³ãŒããããèçœè³ªã¯ã 1451 æ®åºã®ã¢ããé
žããæ§æãããŠããã HJ06972éºäŒåã«ã³ãŒããããèçœè³ªã MTYK ãšåæ§ã« Næ«ç«¯éšåã«ãããŒãŒãã¡ã£ã³ãæãã Cæ«ç«¯ã«ã¯ SH3ãªã¬ã³ããã¡ã€ã³ã æããŠãã ïŒå³ 1 ) ã HJ06972ã®å¡©åºé
åãé
åçªå·ïŒ 1ã«ã ãã®ã¢ããé
žé
åã é
åçªå·ïŒ 2ã«ç€ºããã ãã®å¡©åºé
åãšã¡ããé
žé
åã¯ã HJ06972 (KIAA1079)ãšã ãŠã ããã DNAç 究æã«ãããŠæ§é ãæããã«ãããŠããïŒDNA Research 30ïŒ 6/3, 197-205, 1999, "Prediction of the coding sequences of unidentified human genes, XIV, The complete sequences of 100 new cDNA clones from brain which code for large protein in vitro"ïŒ)ã ããããã®æ©èœã«ã€ããŠã¯ãªã«ã解æãã ãŠããªãã
æ¬çºæã® AF06972éºäŒåã¯ãäžèš HJ06972éºäŒåã®ãã¢å£ãŒã°éºäŒåã®æ€çŽ¢éçšã« ãããŠèŠåºãããã æ¬çºæè
ãã¯ã æ¢ã«å¡©åºé
åãæããã«ãããŠãã HJ06972éº äŒåã®å¡©åºé
åæ
å ±ãå©çšããŠã ESTã®å¡©åºé
åãã¢ã»ã³ãã«ããã ãã®çµæã
HJ06972ã«å¯Ÿã㊠94bpãããªãæ¿å
¥é
åãæããéºäŒåã®ååšãçãããã æ¬çºæ è
ãã¯ããã®æ¿å
¥é
åãæããéºäŒåãæ¢çŽ¢ãã AF06972éºäŒåãèŠåºãããæŽã«ã ããŠã¹ãã©ããã«ããã AF06972éºäŒåã®ãã¢ããŒã°ã®ååšã確èªãã AF06972ãæ° èŠãªéºäŒåã§ããããšã確èªããã ããŠã¹ãã©ããã«ããã AF06972éºäŒåã®ã㢠ããŒã°ã®ååšã¯ç¥ãããŠããªãã
AF06972éºäŒåã¯ã HJ06972éºäŒåã®å¡©åºé
åäžã®ç¬¬ 4623çªç®ã« 94å¡©åºãæ·å
¥ãã ãå¡©åºé
åãããªãã æ¿å
¥å¡©åºé
åã«ãã£ãŠã AF06972éºäŒåãã³ãŒãããã¡ãã é
žé
åã«ã¯ã ãã¬ãŒã ã·ãããçããŠããããã®çµæã Cæ«ç«¯éšäœã«ãã㊠AF06972 éºäŒåã«ããã³ãŒããããèçœè³ªã®æ¹ã HJ06972éºäŒåã«ããã³ãŒããããèçœè³ª ããã 49ã¢ããé
žæ®åºé·ããªã£ãŠããã ãããã£ãŠã HJ06972éºäŒåã«å¯Ÿã㊠AF06972éºäŒåã¯æ°èŠãªéºäŒåãšèšãããšãã§ããã ãã¡ããã AF06972ã«ãã£ãŠã³ ãŒããããã¢ããé
žé
åãããªãèçœè³ªãæ°èŠã§ããããšã¯èšããŸã§ãç¡ãã ãŸãã ããŠã¹ MTYKãšã®æ¯èŒã§ã¯ã AF06972ã®æ¹ã HJ06972ãããçžåæ§ãé«ãã ãšãå€æãã ïŒå³ 4 ) ã ãã MTYKãš AF06972ãšã¯ãé
å㧠20æ°ïŒ
ã®ãã¢ããžäžãæ ãã ãã®ãããŒãŒãã¡ã€ã³ã«ã€ããŠã¯ 41 /0ã®ãã¢ããžäžãèªããããã æ¬çºæã¯ã 以äžã«ç€ºãçŽ 4. 8kbã®éºäŒåã ãããŽè©²éºäŒåã«ããã³äžãããã 1503ã¡ããé
žæ® åºãããªãèçœè³ªã^^ããã AF06972ã®å¡©åºé
åãé
åçªå·ïŒ 3ã«ã ãã®ã¢ãã é
žé
åãé
åçªå·ïŒ 4ã«ç€ºããã
ãŸããæ¬çºæã«ã¯ãé
åçªå·ïŒ 4ã«ç€ºããã¢ããé
žé
åãããªãèçœè³ªãšæ©èœç ã«åçãªèçœè³ªãã³ãŒãããããªãã¯ã¬ãªãããå«ãŸãããããã§ãæ©èœçã«åçã ãšã¯ã察象ãšãªãèçœè³ªãã¢ãããŒã·ã¹èªå°æŽ»æ§ãæã€å ŽåããŸãã¯ç¥çµçªèµ·ã䌞 å±ããã掻æ§ãæããå Žåããã®èçœè³ªã¯æ¬çºæã®æŽ»æ§åã®èçœè³ªãšæ©èœçã«åç ã§ãããšèšãããšãã§ããã
ãããã¯ããªãããã®ããã»ã¹ãçµãŠã¢ãããŒã·ã¹èªå°æŽ»æ§ããŸãã¯ç¥çµçªèµ·äŒž å±äœçšãæã£ã掻æ§åã®èçœè³ªãçæãåŸãèçœè³ªã¯ãæ¬çºæã®èçœè³ªãšæ©èœçã« åçã§ãããäžæŽ»æ§åã®èçœè³ªãã掻æ§åã®èçœè³ªãçæããããã®ããã»ã¹ã¯é
å®ãããªãã
æ¬çºæã«ãããŠã¯ã åäžã®èçœè³ªãã¢ãããŒã·ã¹ ïŒçŽ°èæ»ïŒ ãèªå°ãã掻æ§ã瀺 ããšåæã«ãç¥çµçŽ°èã«å¯ŸããŠã¯ååãå¢æ®ãèªå°ãã掻æ§ã瀺ãã ãããã®æ©èœ ã¯ãéã®äœçšã®ããã«ãæããããã¢ãããŒã·ã¹ã«é¢é£ãããšèããããŠãããã ãŒãŒã®äžã«ã¯ã AATYK (HJ03494)ã ASK- 1ãªã©ãããã ãããã®ãããŒãŒã¯ã éå°çº çŸã«ãã€ãŠã¢ãããŒã·ã¹ãèªå°ããäžæ¹ãç¥çµçªèµ·ã®äŒžå±ã«ãé¢äžããŠããããã ãã®æŽ»æ§ãããããããã®ãã¯ãã·ã°ãã«ã®åŒ·ããšæç¶æéã«å€§ãã圱é¿ãåãã ãšèããããŠããã
HJ06972ãã㎠AF06972ã«ã€ããŠããæ¬çºæè
ãã«ãã€ãŠæ°ãã«åæ§ã®æŽ»æ§ãèŠåº ããããããªãã¡ãããã®èçœè³ªã¯ãç¥çµçªèµ·äŒžå±äœçšãšãšãã«ãéå°çºçŸã«ãã ã¢ãããŒã·ã¹ã®èªå°äœçšãæãããã®ãšèããããã ãããã£ãŠã ãã®çš®ã®ãã㌠ãŒæŽ»æ§ãæããèçœè³ªã«ã¯ãçºçŸã¬ãã«ã®èª¿ç¯çã®æ©æ§ãéããŠãç¥çµçŽ°èæ»ã®ã¿ ãªããç¥çµçŽ°èã®åçã«ã€ãªãããããªäœçšãæåŸ
ãããã
ã¢ãããŒã·ã¹èªå°æŽ»æ§ã¯ãäŸãã°å®æœäŸã«èšèŒããããã«ãåœè©²èçœè³ªãã³ãŒã ããéºäŒåãåºä¹³åç©çŽ°èã«çºçŸããããã®çŽ°èã®ã¢ãããŒã·ã¹ã芳å¯ããããšã« ãã£ãŠç¢ºèªããããšãã§ããã ã¢ãããŒã·ã¹ã¯ã现èã®åœ¢æ
åŠçãªå€åããæè²äœ DNAã®åæãææšãšããŠç¢ºèªããããšãã§ããã ãŸãã ç¥çµçªèµ·äŒžå±äœçšã¯ã äŸã ã°å®æœäŸã«èšèŒããããã«ãåœè©²èçœè³ªãã³ãŒãããéºäŒåãåºä¹³åç©ã®ç¥çµç³»ã® æ ªçŽ°èã«çºçŸããããã®çŽ°èã®ç¥çµçªèµ·ã®äŒžå±ã芳å¯ããããšã«ãã確èªããããš ãã§ããã
ãããæ¬å®æœäŸã«ãããŠåå®ãããèçœè³ªãšæ©èœçã«åçãªèçœè³ªã¯ãåœæ¥è
㧠ããã°ãäŸãã°ãèçœè³ªäžã®ã¢ããé
žé
åã«å€ç°ãå°å
¥ããæ¹æ³ãå©çšããŠèª¿è£œã ãããšãã§ãããå€ç°ã®å°å
¥æ¹æ³ãšããŠã¯ãäŸãã°ãéšäœç¹ç°çå€ç°èªçºæ³ (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. Jonn Wiley & Sons Section 8. 1- 8. 5)çã瀺ãããšãã§ããã ãŸãã ãã®ãããªèçœè³ªã¯èªç¶ çã«ãããã¢ããé
žã®å€ç°ã«ããçããããšããããæ¬çºæã«ã¯ã ãã®ããã«æ¬å®
æœäŸã«ãããŠåå®ãããèçœè³ªãšåçã®æ©èœãæããéãããã®ã¢ããé
žé
åïŒé
åçªå·ïŒ 2ã ãŸã㯠4 ) ã«ãã㊠1è¥ããã¯æ°åã®ã¢ããé
žã眮æã æ¬ å€±ã æ·å
¥ã ããã³/ãŸãã¯ä»å çã«ããç°ãªãèçœè³ªãå«ãŸããã
èçœè³ªã«ãããã¡ããé
žã®å€ç°æ°ãå€ç°éšäœã¯ããã®æ©èœãä¿æãããéãç¹ã« å¶éãããªãã å€ç°æ°ã¯ãå
žåçã«ã¯ãå
šã¢ããé
žã® 10%以å
ã§ããã奜ãŸãã㯠å
šã¢ããé
žã® 5%以å
ã§ããã ããã«å¥œãŸããã¯å
šã¢ããé
žã® 1%以å
ã§ããã眮æ ãããã¢ããé
žã¯ãèçœè³ªã®æ©èœä¿æã®èŠ³ç¹ããã眮æåã®ã¢ããé
žãšäŒŒãæ§è³ªã æããã¢ããé
žã§ããããšã奜ãŸããã äŸãã°ã Alaã Valã Leu, Ileã Pro, Metã Phe Trpã¯ãå
±ã«é極æ§ã¢ããé
žã«åé¡ããããããäºãã«äŒŒãæ§è³ªãæãããšè ããããã ãŸãã éè·é»æ§ãšããŠã¯ã Glyã Serã Thrã Cysã TyrN Asnã Ginãæã ãããã ãŸãã é
žæ§ã¢ããé
žãšããŠã¯ã Aspããã³ Gluãæããããã ãŸããå¡©åºæ§ ã¢ããé
žãšããŠã¯ã Lysã Argã Hisãæããããã
ãŸããæ¬çºæã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã¯ãåœæ¥è
ã«åšç¥ã®ãã€ããªã〠ãŒãŒã·ã§ã³æè¡ãããã¯éºäŒåå¢å¹
æè¡ãå©çšããŠåé¢ããããšãå¯èœã§ãããå³ ã¡ã åœæ¥è
ã§ããã°ã ãã€ããªãã£ãŒãŒã·ãšã³æè¡ (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publisn. John Wiley & Sons Section 6. 3- 6. 4)ãçšããŠæ¬çºæã®èçœè³ªãã³ãŒãããå¡©åºé
å ïŒé
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3 )ãŸãã¯ãã®äžéšãããšã«ãããšçžåæ§ã®é«ãããªãã¯ã¬ãªã ããåé¢ããŠã ãã®ããªãã¯ã¬ãªããããæ©èœçã«åçãªèçœè³ªãåŸãããšã¯ãé åžžè¡ãåŸãããšã§ããã æ¬çºæã«ã¯ã æ¬çºæã®èçœè³ªãšåçã®æ©èœãæããéãã ããã«ããã³ãŒããããèçœè³ªãå«ãŸããã
æ©èœçã«åçãªèçœè³ªãã³ãŒãããããªãã¯ã¬ãªãããåé¢ããããã®ãã€ã ãªãã€ãŒãŒã·ãšã³ã®ã¹ããªã³ãžã§ã³ããªæ¡ä»¶ã¯ã éåžžã¯æŽæµã®ããã®æ¡ä»¶ãšã㊠ãlxSSCã 0. 1% SDSã 37°Cã çšåºŠã§ããã ããå³ããæ¡ä»¶ãšããŠã¯ ã0. 5xSSCã 0. 1% SDSã 42ã§ã çšåºŠã§ããã ããã«å³ããæ¡ä»¶ãšããŠã¯ ã0. lxSSCã 0. 1% SDSN 65°Cã
çšåºŠã§ããããã€ããªãã€ãŒãŒã·ã§ã³ã®æ¡ä»¶ãå³ãããªãã»ã©ãããŒãé
åãšé«ã çžåæ§ãæãã DNAã®åé¢ãæåŸ
ãåŸãã äœãã äžèš SSCã SDSããã³æž©åºŠã®æ¡ä»¶ã® çµã¿åããã¯äŸç€ºã§ãããåœæ¥è
ã§ããã°ããã€ããªãã€ãŒãŒã·ã§ã³ã®ã¹ããªã³ãž ã§ã³ã·ãŒã決å®ããäžèšè¥ããã¯ä»ã®èŠçŽ ãé©ïŒ^äžã¿åãããããšã«ãããäžèšãš åæ§ã®ã¹ããªã³ãžãšã³ã·ãŒãå®çŸããããšãå¯èœã§ãããã¹ããªã³ãžãšã³ã·ãŒã«åœ± é¿ãäžãããã®ä»ã®æ¡ä»¶ãšããŠããããŒãæ¿åºŠããããŒãã®é·ãããã€ããªãã€ãŒ ãŒã·ã§ã³åå¿æéãªã©ã瀺ãããšãã§ããã
ãã®ãããªãã€ããªãã€ãŒãŒã·ã§ã³æè¡ãå©çšããŠåé¢ãããèçœè³ªã¯ãé
åçª å·ïŒ 4ã«èšèŒã®æ¬çºæã®èçœè³ªãšæ¯èŒããŠãéåžžããã®ã¢ããé
žé
åãŸãã¯è©²èçœ è³ªãã³ãŒãããå¡©åºé
åã«ãããŠé«ãçžåæ§ãæãããé«ãçžåæ§ãšã¯ãå°ãªããš ã 60%以äžã奜ãŸãã㯠70%以äžã ããã«å¥œãŸãã㯠80%以äžïŒäŸãã°ã 90%以äžïŒ ã®é
åã®åäžæ§ãæããçžåæ§ã®ç¹å®ã¯ã BLAST2æ€çŽ¢ã¢ã«ãŽãªãºã ïŒAltschul, S. F. et al, 1997 Gapped BLAST and PSI - BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25: 3389-3402. )ãçšããŠæ±ºå®ããããšã㧠ããã
ãŸãã éºäŒåå¢å¹
æè¡ (PCR) (Current protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley Sons Section 6. 1â6. 4) ãçšããŠã æ¬å®æœäŸã«ãããŠåå®ãããå¡©åºé
å ïŒé
åçªå·ïŒ 1ã ãŸã㯠3 ) ã®äžéšãããšã« ãã©ã€ããŒãèšèšãã ãããå¡©åºé
åãŸãã¯ãã®äžéšãšçžåæ§ã®é«ã DNAæçãå é¢ããŠããããããšã«æ¬çºæã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªãåŸãããšãå¯èœã§ ãããæ¬çºæã®èçœè³ªã䞊ã³ã«æ¬çºæã«ãããæ©èœçã«åçãªèçœè³ªã¯ãåŸã«è¿°ã¹ ããããªã åœè©²èçœè³ªã®æ©èœã修食ããååç©ã®è©äŸ¡æ¹æ³ã«çšããããšãã§ããã ãŸããããã®èçœè³ªãã³äžãããããªãã¯ã¬ãªããã¯ãåœè©²èçœè³ªã®è£œé ãçºçŸç¶ æ
ãç¥ãããã®ãã©ã€ããŒãŸãã¯ãããŒããšããŠæçšã§ããã
ãããã¯æ¬çºæã¯ãæ¬çºæã®èçœè³ªã«å¯ŸããŠãããã³ããã¬ãã£ãã®åœ¢è³ªãæã ãèçœè³ªãã³ãŒãããããªãã¯ã¬ãªããã«é¢ããã ãããã³ããã¬ãã£ãã®åœ¢è³ªã
æããèçœè³ªãã³ãŒãããããªãã¯ã¬ãªããã¯ããã®çºçŸã«ãã€ãŠçŽ°èãããšããš åããŠããå
åšæ§ã®éçåèçœè³ªã®æŽ»æ§ãæ¶å€±ãããã¯äœäžãããæ©èœãæããã äŸãã°ã æ¬çºæã®ã¢ãããŒã·ã¹é¢é£å åã«ããããããŒãŒãã¡ã€ã³ã SH3ãªã¬ã³ã ãã¡ã£ã³çã該èçœè³ªã®æŽ»æ§ã«åœ±é¿ãããšèããããé
åã«çžåœããéšåã®ã¡ãã é
žé
åãæ¹å€ããã°ãã¢ãããŒã·ã¹èªå°æŽ»æ§ãç¥çµçªèµ·äŒžå±äœçšãæããªãäžæŽ»æ§ äœãåŸãããšãã§ãããšèããããããã®ãããªã¢ããé
žé
åãã³ãŒãããéºäŒå ã现èå
ã«çºçŸãããã°ãæ¬çºæã®ã¢ããäžã·ã¹é¢é£å åã®çºçŸããããã³ãã㬠ãã£ãå¹æ (äžæŽ»æ§åã®æ®æé»å®³ïŒã«ããæå¶ããããšãã§ãããåŸã£ãŠã ãŠã£ã«ã¹ ã¹ã¯ã¿ãŒçã®éºäŒåå°å
¥æè¡ã«ãã£ãŠãäžæŽ»æ§äœéºäŒåã现èã«å°å
¥çºçŸãããã ãšã§ãã¢ãããŒã·ã¹ã®é²è¡ãé»å®³ããããç¥çµçŽ°èã®ååãã㎠ZãŸãã¯å¢æ®ãæ å¶ãããããããšãå¯èœãšãªãã
æ¬çºæã¯ã ãŸãã æ¬çºæã®èçœè³ªã®éšåãããããæäŸããã éšåããããã¯ã æ¬çºæã®èçœè³ªã«å¯ŸããæäœãåŸãããã®å
ç«åãšããŠæçšã§ãããç¹ã«ãä»ã®è çœè³ªãšã®çžåæ§ãäœããæ¬çºæã®èçœè³ªã«åºæã®ã¡ããé
žé
åãå«ãéšåã¹ããã ã¯ã æ¬çºæã®èçœè³ªã«å¯ŸããŠç¹ç°æ§ã®é«ãæäœãäžããå
ç«åãšããŠæåŸ
ãããã ãã®ãããªã¢ããé
žé
åãšããŠãé
åçªå·ïŒ 6ã«ç€ºãã¢ããé
žé
åããéžæããã ã¡ããé
žé
åãæããããšãã§ããã
æ¬çºæã®éšåã¹ãããã¯ã -å°ãªããšã 7ã¢ããé
žã奜ãŸãã㯠9ã¡ããé
žä»¥äžã ã ã奜ãŸãã㯠12ã¡ããé
žä»¥äžããã奜ãŸãã㯠15ã¡ããé
žä»¥äžã®ã¡ããé
žé
åãã ãªããæ¬çºæã®éšåããããã¯ãäŸãã°ãéºäŒåå·¥åŠçææ³ãå
¬ç¥ã®ããããåæ æ³ããããã¯æ¬çºæã®èçœè³ªãé©åœãªãºããããŒãŒã§åæããããšã«ãã£ãŠè£œé ã ãããšãã§ããã
ãŸãæ¬å³æã¯ãåèšããªãã¯ã¬ãªããã®ãããããå«æããçºçŸãã¯ã¿ãŒãæäŸ ããã ããã«ãæ¬çºæã¯ãåèšããªãã¯ã¬ãªããã ãããã¯åèšããããã®çºçŸã¹ ã¯ã¿äžãä¿æãã圢質転æäœã䞊ã³ã«ãã®åœ¢è³ªè»¢æäœãå¹é€ãããã®å¹é€ç©ããæ¬ çºæã®èçœè³ªãåé¢ããå·¥çšãå«ããæ¬çºæã®èçœè³ªããããã¯ãã®éšåãããã
ã®è£œé æ¹æ³ã«é¢ããã ããã«æ¬çºæã¯ãäžèšã®æ¹æ³ã§è£œé ãããèçœè³ªãæãã¯ã ã®éšåã¹ããããæäŸããã
éºäŒåçµæãææ³ã§ããªãããããçç£ããå Žåã宿䞻现èã®çš®é¡ã«ããã ç®ç ããªãºãããã®ã°ãªã³ã·ã«åã®çš®é¡ãçšåºŠã®ç°ãªã€ããã®ãåŸãããããšãããã ããããªãºãããã®åæ³çç£æ³ã«ãããŠã宿䞻现èäžã§çºçŸãããåé§äœããªãºã ããã®æ«ç«¯ (Nâæ«ç«¯ãã㎠ZãŸã㯠Câæ«ç«¯)ã¡ããé
žé
åãã·ã°ãã㬠·ãºããã ãŒãŒçã«ããããã»ãã·ã³ã°ãåããçš®ã
ã®æ«ç«¯ã¡ããé
žé
åãæã€ããªãããã ãåŸãããããšã¯åœæ¥è
ã«åšç¥ã§ãããåŸã£ãŠããã®ãããªããªãããããæ¬çºæ ã®èçœè³ªã®ç¯å²ã«å«ãŸããããšã¯ã åœæ¥è
ãªãã°å®¹æã«ç解ãåŸãããšã§ããã äžèšå®æœäŸã«ã¯ãçºçŸãã¯ã¿ãŒãšããŠåºä¹³é¡åç©çŽ°èå
ã§æ©èœããã¹ã¯ã¿ãŒã®æ§ ç¯äŸã®ã¿ã瀺ãããŠããã ããããªãããæ¬çºæã®èçœè³ªãã³ãŒããã D NAãé 瀺ãããŠããçµæã ãããã«åºã¥ããŠãé
µæ¯çã®çèé¡ã䞊ã³ã«åæ žæ§çŽ°è宿䞻㫠å°å
¥ãããšãã該宿䞻ã«æ¬çºæã®èçœè³ªãçºçŸãç£çããåŸãçºçŸãã¯ã¿ãŒãæ§ç¯ ããããšã¯åœæ¥è
ã«ãšã£ãŠå®¹æã§ãããåŸã£ãŠãæ¬çºæã¯ãæ¬çºæã®æ žé
žé
åã«åº ã¥ãã åœè©²æè¡åéæ¢ç¥ã®æ¹æ³ã§æ§ç¯ãããçºçŸã¹ã¯ã¿äžããå
å«ããã
æ¬çºæã®èçœè³ªãã³ãŒãããããªãã¯ã¬ãªãããçºçŸãããããã«çšãåŸã埮 çç©çŽ°èã«ã¯ã äŸãã°ã åæ žæ§ã®çŽ°è [倧è
žè (fe^ari^is ãæ¯èè (Bacillus subtil is) ]ãããŽçæ žæ§ã®é
µæ¯ [äŸãã°ãã³é
µæ¯è Saccaråµ ces core 's ae) ]ãããããŸããåºä¹³é¡çŽ°èã«ã¯å¹é€ãã现èãããŽå¹é€åç©çŽ°èãå« ãŸããã ããã«ã¯å¹é€æ€ç©çŽ°èãçšãåŸãã
埮çç©ã®äŸãšããŠã¯ã§ã·ãšãªãã¢å±ã«å±ãã现èããã³é
µæ¯ããããããå
·äœç ã«ã¯ã äŸãã°æ¬¡ã®ãããªèæ ªã埮çç©å®¿äž»ãšããŠæããããšãã§ããã
ã§ã·ã§ãªãã¢å±ã«å±ãã现è
K coli HB10KATCC 33694)
K coli HB101-16 (FERM BP- 1872)
E. coli MM294(ATCC 31446)
K coli DH1 (ATCC 33849)ç
ãã³é
µæ¯
S. cerevisiae AH22 (ATCC 38626)ç
åºä¹³åç©çŽ°èã®äŸãšããŠã¯ããèå
è
èç±æ¥ H E K 2 9 3现èãããŠã¹ L 9 2 9 现èããã³ãã£ã€ããŒãº.ãã ã¹ã¿ãŒ ·ã©ããªãŒïŒC H O)现èçãããã
éåžžãåæ žçç©ã§ãã现èãç¹ã«å€§è
žèã宿䞻现èãšããŠçšããå ŽåãçºçŸã¹ã¯ ã¿ãŒã¯å°ãªããšãããã¢ãŒã¿ãŒãéå§ã³ãã³ãæ¬çºæã®èçœè³ªã®ã¢ããé
žé
åãã³ ãŒãããããªãã¯ã¬ãªãããçµæ¢ã³ãã³ãããŽèªå·±è€è£œå¯èœã¥ãããããæ§æãã ããçæ žçç©ãå³ã¡é
µæ¯ãåºä¹³åç©çŽ°èã宿䞻现èãšããŠçšããå ŽåãçºçŸã¹ã¯ã¿ äžã¯ãå°ãªããšãããã¢ãŒã¿ãŒãéå§ã³ãã³ãæ¬çºæã®èçœè³ªã®ã¢ããé
žé
åãã³ ãŒãããããªãã¯ã¬ãªããããã³çµæ¢ã³ãã³ããæ§æãããã®ã奜ãŸãããããã« ã§ã³ãã³ãµãŒé
åãæ¬çºæã®èçœè³ªã® 5 'âããã³ 3ïŒäžéã³ãŒãé åãããªã¢ãã ã«ã€åéšäœãããŽèªå·±è€è£œå¯èœåäœãæ¿å
¥ããããšãã§ããã
äžèšã®èªå·±è€è£œå¯èœåäœã¯ã 圢質転æäœã®éžæããŒã«ãŒ (äŸãã°ã ã¡ã³ãã·ãªã³ èæ§ïŒãå«æããŠããããšã奜ãŸããã 现èã宿䞻ãšããçºçŸãã¯ã¿ãŒã®å Žåã ã å£ã¢ãŒã¿ãŒãšããèªå¥ã¯ãããã¢ãŒã¿ãŒããªãã¬ãŒã¿ãŒãããŽã·ã£ã€ã³äžããã¬ã¬ãŒ ãïŒ S D)é
å (äŸãã° A AG GçïŒãããªãããã¢ãŒã¿ãŒ ·ãªãã¬ãŒã¿ãŒé åãæå³ ããã ãã®ãããªããã¢ãŒã¿ãŒã®äŸãšããŠã¯ãæ
£çšã®ããã¢ãŒã¿ãŒ ·ãªãã¬ãŒã¿äž é åãæããããã å
·äœçã«ã¯ã ã©ã¿ããŒã¹ã©ããã³ã P Lâããã¢ãŒã¿ãŒã ãã ã㯠trpâããã¢ãŒã¿ãŒçã瀺ãããšãã§ããã é
µæ¯ã宿䞻ãšããçºçŸãã¯ã¿ãŒã« çšããããããã¢ãŒã¿ãŒã®äŸãšããŠã¯ pho 5ããã¢ãŒã¿ãŒãæ³ããããã æŽã«ã 粟 補ã容æã«è¡ãããšãç®çãšããŠãéå±ã€ãªã³ãã¬ãŒãã«å¯Ÿãã芪åæ§ãæã€å¡©åº æ§ã¡ããé
žãã æ¬çºæã®èçœè³ªã«ãããããããã®æ«ç«¯ã«ä»å ããããšãã§ããã å¡©åºæ§ã¢ããé
žãä»å ããå Žåã«ã¯ãåžæã®ã¢ããé
žãã³ãŒãããå¡©åºé
åãé£ç¶ ããå¡©åºé
åã 5'åŽã«ä»å ãããã©ã€ããŒãçšããŠã P C Rãè¡ãã°ã ç®çãšãã éºäŒåã®ä»»æã®æ«ç«¯ã«ããªãªãŽãããããä»å ããããšãã§ãããå¡©åºæ§ã¢ããé
ž
ãšããŠã¯ã ãã¹ããžã³ã ãªãžã³ã ãããã¯ã¢ã«ã®ãŠã³ãªã©ãçšããããšãã§ããã åºä¹³åç©çŽ°èã«ãããçºçŸãã¯ã¿ãŒã«çšããããããã¢ãŒã¿ãŒã®äŸãšããŠã¯ã H TLVâ LTRããã¢ãŒã¿äžã SV40åæãããŽåŸæããã¢ãŒã¿ãŒã CMVãã ã¢ãŒã¿ãŒã ããŠã¹ ·ã¡ã¿å£ãã©ãã€ã³ I(MMT)âããã¢ãŒã¿ãŒçãæããããã 奜ãŸããéå§ã³ãã³ã®äŸãšããŠã¡ãã©ãã³ã³ãã³ïŒATG)ãæããããã
çµæ¢ã³ãã³ã®äŸãšããŠã¯æ
£çšãããŠããçµæ¢ã³ãã³ïŒäŸãã° TAGã TGAãçïŒ ãæããããã èªå·± å¯èœãŠããããšã¯ããããå«æããçºçŸãã¯ã¿ãŒã®å
š DN Aã宿䞻现èäžã§èªå·±è€è£œãåŸã DN Aé
åã§ãã£ãŠã倩ç¶ã®ãã©ã¹ããã人工ç ã«ä¿®é£Ÿãããã©ã¹ãããããã³åæãã©ã¹ãããæããããã人工çã«ä¿®é£Ÿããã ã©ã¹ããã«ã¯ãäŸãã°å€©ç¶ãã©ã¹ãããã調補ãã DNAæççãå«ãŸããããã® ãããªãã©ã¹ããã®å¥œãŸããäŸãšããŠã¯ã倧è
žèã宿䞻现èãšããå ŽåãäŸãã°ã ã©ã¹ãã pBR322ããã®äººå·¥ä¿®é£Ÿäœãæããããã人工修食äœãšã¯ãããšãã° p B 322ã®é©åœãªå¶éé
µçŽ åŠçã«ãã£ãŠåŸããã DN Aæççã瀺ãããšã㧠ããã ãŸãé
µæ¯ã宿䞻现èãšããå Žåã«ã¯ãäŸãã°ã pJDB 219ã pJDB 20 7çãæããããã ããã«ã åç©çŽ°èçšãã©ã¹ãããšããŠã¯ã äŸãã°ãã©ã¹ãã pcDNA3.1 (Invitrogen) ã p顧 324ã ãã©ã¹ãã PSV2dhfr (ATCC37145) ã ãã©ã¹ã ã pdBPV - MTneo (ATCC37224) ã ãã©ã¹ãã pSV2neo (ATCC37149) ãæããããã ã§ã³ãã³ãµãŒé
åãšããŠã¯ã äŸãã° SV40ã®ã§ã³ãã³ãµãŒé
åãæããããã ããªã¡ãã¥ã«åéšäœãšããŠã¯ãäŸãã° S V 40ã®ããªã¢ããã«åéšäœãæããããã æ¬çºæã®èçœè³ªã®ã¢ããé
žé
åãã³äžãããããªãã¯ã¬ãªããã¯ãäŸãã°ã DN Aåæè£
眮ãçšããŠã éšååæãŸãã¯å
šåæããããšã«ãã£ãŠåŸãããšãã§ããã æãã¯ã ãã cDNAã©ã€ãã©ãªãŒãããé
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åã«åºã¥ããŠèš å®ãããããŒãããã©ã€ããŒãçšããŠååŸããããšãã§ãããæŽã«ãã²ãã DNA ãåžžæ³éãåŠçããããšã«ãã£ãŠã æ¬çºæã®èçœè³ªãã³ãŒãããã²ãã DNAã調補 ããããšãã§ãããã²ãã DNAã®åŠçæ¹æ³ãšããŠã¯ãäŸãã°ãå¶éé
µçŽ ã«ããæ¶åã 现èã¡ /ã¬ã«ãªãã¹ãã¡ã¿ãŒãŒã«ããè±çé
žåã T 4ããªãã¯ã¬ãªãããããŒãŒã«ã
ãæé
žåãããã³ T 4 D N Aãªã¬ãŒãŒãçšããã©ã€ã²ãŒã·ã§ã³çã®å·¥çšãå«ãåŠç æ¹æ³ã瀺ãããšãã§ããã æŽã«ãã®ããã«ããŠååŸããã²ãã DNAãå©çšãã ã²ã ã ã«ãããæ¬çºæã®éºäŒåã®è»¢åéå§ç¹ãæããã«ããããäžæµã«äœçœ®ããçºçŸå¶ 埡é åãç¹å®ããããšãã§ãããæ¬çºæã®èçœè³ªãã³ãŒãããéºäŒåã®çºçŸãå¶åŸ¡ ããããã¢ãŒã¿ãŒãã§ã³ãã³ãµäžçã®å¶åŸ¡é åã¯ãæ¬çºæã®èçœè³ªã®çºçŸç°åžžãæ€ åºããããã®æšçé åãšããŠæçšã§ãããæãã¯ã ãããã®é åãæšçãšãããã³ ã£æ žé
žå»è¬ãªã©ã«ããã çºçŸå¶åŸ¡ãå®çŸããããšãã§ããã
æ¬çºæã®å®æœã«å¿
èŠãªã D NAã®ã¯ããŒãŠã³ã°ãåãã©ã¹ããã®æ§ç¯ã宿䞻ã®ã ã©ã³ã¹ããšã¯ã·ãšã³ã圢質転æäœã®å¹é€ããã³å¹é€ç©ããã®èçœè³ªã®ååçã®æäœ ã¯ãåœæ¥è
æ¢ç¥ã®æ¹æ³ããããã¯æç®èšèŒã®æ¹æ³ [Molecular Cloning 2nd. edition, J. Sambrook et. al, Cold Springs Harbor Laboratory (1989) , DNA Cloning, DM. Glover, IRL PRESS (1985)ä»ã Molecular Cloning 3rd. edition, J. Sambrook et. al, Cold Springs Harbor Laboratory (2001) ]ã«æºããŠè¡ãªãããšãã§ããã
ãŸããæ¬çºæã®å®¿äž»çŽ°èã«ã¯ãæ¬çºæã®ã¢ãããŒã·ã¹é¢é£å åã®æ©èœè§£æããã® èçœè³ªãå©çšãããã®æ©èœé»å®³å€ãæ©èœä¿é²å€ã®è©äŸ¡æ¹æ³ã®ããã«çšããç®ç㮠现èãå«ãŸããã宿䞻现èãžã®ãã¯ã¿ãŒå°å
¥ã¯ãäŸãã°ããªã³é
žã«ã«ã·ãŠã æ²æ®¿æ³ã é»æ°" ^ãã¬ã¹ç©¿å Lãfe (Current protocols in Molecular Biology edit. A subel et al. (1987) Publish. John Wiley & Sons. Section 9. 1-9. 9) ã ãªãããšã¯ã¿ãã³æ³
(GIBC0-BRLŸ ) ã ãã€ã¯ãã€ã³ãžã§ã¯ã·ã§ã³æ³çã®æ¹æ³ã§è¡ãããšãå¯èœã§ã ãã圢質転æäœããã®æ¬çºæã®èçœè³ªã®èª¿è£œã¯ã åœæ¥è
ã«å
¬ç¥ã®èçœè³ªã®åé¢'粟 補æ³ãå©çšããŠè¡ãªãããšãã§ããã
æ¬çºæã¯ãŸããé
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ãªãããŸã㯠ãã®çžè£éã«çžè£çãªå°ãªããšã 15ãã¯ã¬ãªãããå«ãããªãã¯ã¬ãªãããæäŸ ããã ãã㧠ãçžè£éã ãšã¯ã A:T (A:U) ã G:Cã®å¡©åºå¯Ÿãããªã 2æ¬éããªãã¯ã¬ ã©ããã®äžæ¹ã®éã«å¯Ÿããä»æ¹ã®éãæãã ãŸãã ãçžè£çã ãšã¯ãå°ãªããšã 15 åã®é£ç¶ãããã¯ã¬ãªããé åã§å®å
šã«çžè£é
åã§ããå Žåã«éããããå°ãªããš
ã 70%ã奜ãŸããã¯å°ãªããšã 80%ã ãã奜ãŸãã㯠90%ã ããã«å¥œãŸãã㯠95%以 äžã®å¡©åºé
åäžã®çžåæ§ãæããã°ãããçžåæ§ã決å®ããããã®ã¢ã«ãŽãªãºã 㯠æ¬æ现æžã«èšèŒãããã®ã䜿çšããã°ããã
ãã®ãããªããªãã¯ã¬ãªããã¯ã æ¬çºæã®èçœè³ªãã³ãŒããã DMã RNAãæ€åºã åé¢ããããã®ãããŒããšããŠããŸããæ¬çºæã®ããªãã¯ã¬ãªãããå¢å¹
ãããã ã®ãã©ã€ããŒãšããŠå©çšããããšãå¯èœã§ããããã©ã€ããŒãšããŠçšãã;^ã«ã¯ã éåžžã 15bPã100bPã 奜ãŸãã㯠15bpã35bpã®éé·ãæããã ãŸãã ãããŒããšã ãŠçšããå Žåã«ã¯ãæ¬çºæã®ããªãã¯ã¬ãªããã®å°ãªããšãäžéšè¥ããã¯å
šéšã®é
åãæããå°ãªããšã 15bpã®éé·ã®ããªãã¯ã¬ãªãããçšããããããã©ã€ããŒãš ããŠçšããå Žåã 3'åŽã®é åã¯çžè£çã§ããå¿
èŠããããã 5'åŽã«ã¯å¶éé
µçŽ èªè é
åãã¿ã°ãªã©ãä»å ããããšãã§ããã
ç¹ã«ãé
åçªå·ïŒ 3ã«ç€ºãå¡©åºé
åã®ãã¡ãé
åçªå·ïŒ 5ã«èšèŒãããå¡©åºé
å ãå«ãé åããŸãã¯ãã®çžè£é
åã«ãã€ããªãã£ãºããããšãã§ãããªãªãŽãã¯ã¬ ã©ããã¯ã AF06972ãç¹ç°çã«æ€åºããããã®ãããŒãã ãããã¯ãã©ã€ããŒãšã ãŠæçšã§ããã
ãããã¯ãé
åçªå·ïŒ 3ã«ç€ºãå¡©åºé
åã®ãã¡ãé
åçªå·ïŒ 5ã«èšèŒãããå¡©åº é
åãããªãé åãå¢å¹
ããããšãã§ãããã©ã€ããŒã¯ã HJ06972ãš AF06972ã®äž¡æ¹ ã 1çµã®ãã©ã€ããŒã«ãã£ãŠå¢å¹
ããããšãã§ããããããåœè©²ãã©ã€ããŒã«ã〠ãŠåŸãããå¢å¹
çæç©ã«ã¯ã HJ06972ãš AF06972ãšã§ã¯é
åçªå·ïŒ 3ã®æ§æå¡©åºæ°ã§ ãã 9 4 bpã®çžéãçããã ãããã£ãŠã ãã®ãããªãã©ã€ããŒãçšããããšã«ã ãã HJ06972ãš AF06972ãšãåºå¥ããŠæ€åºã ãããã¯ç¢ºèªããããšãã§ããã
æ¬çºæã®ããªãã¯ã¬ãªããã¯ãæ¬çºæã®èçœè³ªã®ç°åžžãæ€æ» ·蚺æããããã«å© çšããããšãã§ãããäŸãã°ãæ¬çºæã®ããªãã¯ã¬ãªããããããŒãããã©ã€ã㌠ãšããŠçšããããŒã¶ã³ãã€ããªãã€ãŒäžã·ã§ã³ã RT - PCRã«ãããçºçŸç°åžžãæ€æ»ã ãããšãã§ããããŸãæ¬çºæã®ããªãã¯ã¬ãªããããã©ã€ãäžãšããŠçšããããªã¡ ã©ãŒãŒé£éåå¿ (PCR)ã«ãããã²ãã DNA - PCRã RT - PCRãå®æœããããšãã§ãããæŽ
ã«ã æ¬çºæã®èçœè³ªãã³ãŒãããéºäŒåããã®çºçŸå¶åŸ¡é åãå¢å¹
ãã RFLP解æã SSCPã ã·ãŒã¯ã§ã³ã·ã³ã°çã®æ¹æ³ã«ãããé
åã®ç°åžžãæ€æ»'蚺æãããããããš ãã§ããã
ãŸãã æ¬çºæã®ã¢ãããŒã·ã¹é¢é£å å ïŒAF06972) ã¯ç¥çµåçã è³æ¢å¡æ²»çã ç¥ çµè»žçŽ¢åçãç¥çµè»žçŽ¢äŒžå±ã«çšããããšãã§ããããšããã該å åãã³ãŒãããã ãªãã¯ã¬ãªãããã該å åãé¢é£ããçŸæ£ã®éºäŒåæ²»çã«çšããããšãå¯èœã§ããã å³ã¡ã宿䞻ã®çŸæ£éšäœã«ãããŠé©åã«çºçŸããããã該ããªãã¯ã¬ãªãããå°å
¥ã ãããšã«ãããæ¬çºæã®ã¢ãããŒã·ã¹é¢é£å åãçºçŸããã該å åãé¢é£ããçŸæ£ ãæ²»ç'äºé²ããããšãå¯èœã§ããã æ¬çºæã«ãã㊠ãçºçŸã ãšã¯ã 転åããã³/ ãŸãã¯ç¿»èš³ãå«ãŸãããæ¬çºæã®ããªãã¯ã¬ãªãããçšããçºçŸã®è§£æã«ãããéº äŒåã®è»¢åã¬ãã«ã§ã®çºçŸãæ€æ».蚺æããããšãã§ããã ãŸããåŸè¿°ã®æ¬çºæã® èçœè³ªã«å¯Ÿããæäœãçšããã°ãéºäŒåã®ç¿»èš³ã¬ãã«ã§ã®çºçŸãæ€æ» ·蚺æããã ãšãã§ããã
æ¬çºæã«ããã HJ06972ããã㯠AF06972ã¯ãããããã¢ãããŒã·ã¹ã«å¯æ¥ã«é¢é£ ããèçœè³ªãã³ãŒãããéºäŒåã§ãããããšãã°ã人çºçã«ã¢ãããŒã·ã¹ãèªå°ã ãè¡æ¶²çŽ°èã§ã¯ããããã®éºäŒåã®çºçŸã¬ãã«ãã¢ãããŒã·ã¹ã®é²è¡ã«ãšããªã£ãŠ å¢åŒ·ãããã ãããã£ãŠãçäœè©Šæäžã®ãããã®éºäŒåã®çºçŸã¬ãã«ã¯ãã¢ãã㌠ã·ã¹ã®é²è¡ç¶æ
ã®èšºæææšãšããŠæçšã§ãããããšãã°ãåçèçã®ãããªæ¥æ¿ãª ã¢ãããŒã·ã¹ã®é²è¡ãèŠãããçŸæ£ã«ãããŠã¯ã HJ06972ããã㯠AF06972ã®çºçŸã¬ ãã«ã®æ¥æ¿ãªäžæã蚺æææšãšããããšãã§ããã
å ããŠæ¬çºæã¯ãçäœè©Šæäžã®ã¢ãããŒã·ã¹ããŒã«ãŒã枬å®ãã該ã¢ããäžã·ã¹ ããŒã«äžã®æž¬å®ã¬ãã«ã®äžæãåœè©²çäœè©Šæã«ãããã¢ããäžã·ã¹ã瀺ãå·¥çšã å«ãã¢ãããŒã·ã¹ã®æ€åºæ¹æ³ã§ãã£ãŠãã¢ãããŒã·ã¹ããŒã«ãŒã次ã®ïŒa ) â ( e ) ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã ãŸã㯠ïŒa ) â ( e ) ã®ããããã«èšèŒã® ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªã§ããæ¹æ³ãæäŸããã
( a ) é
åçªå·ïŒ 3ã«èšèŒãããå¡©åºé
åãå«ãããªãã¯ã¬ãªããã
( b )é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãã³ãŒãããããªãã¯ã¬ ã©ããã
( c ) é
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åãå«ã¿ã ãã€é
åçªå·ïŒ 4ã«èšèŒã®ã¢ã ãé
žé
åã«ãããŠã 1è¥ããã¯æ°åã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ã ããã³/ ãŸãã¯ä»å ããã¡ããé
žé
åãããªããé
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
žé
åã ããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããããªãã¯ã¬ãªããã
( d ) é
åçªå·ïŒ 5ã«èšèŒã®å¡©åºé
åãå«ã¿ãé
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãã ãªãããªãã¯ã¬ãªãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããé
å çªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒ ãããããªãã¯ã¬ãªããã ããã³
( e )é
åçªå·ïŒ 5ã«èšèŒã®å¡©åºé
åããéžæãããå¡©åºé
åãå«ã¿ããã€é
åçª å·ïŒ 3ã«èšèŒã®å¡©åºé
åãš 7 0 %以äžã®ãã¢ããžäžãæããé
åçªå·ïŒ 4ã«èš èŒã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããã㪠ãã¯ã¬ãªããã
AF06972éºäŒåã¯è³ä»¥å€ã®çµç¹ã«ãããŠã¯æåžžçãªçºçŸã¯èŠãããªãã ä»æ¹ã ã¡ ãããŒã·ã¹ãèµ·ããã现èã§ã¯çæéã®ãã¡ã«ã AF06972éºäŒåã®çºçŸã¬ãã«ãäž æãããããšãã°ããŠã¹ã®çŽ°èãçšããå®éšã«ãããŠã¯ãè¡æ¶²çŽ°èã®ã¢ãããŒã·ã¹ ã®èªå°ã«äŒŽã£ãŠã MTYKããã㯠AF06972ã®çºçŸã¬ãã«ãæ¥æ¿ã«äžæããŠããã ãã ãã£ãŠã MTYKã AF06972N ãããã¯ãããšæ©èœçã«åçãªéºäŒåãã¢ãããŒã·ã¹ã äžåäžãšããŠæž¬å®ããããšã«ãã£ãŠã ã¢ãããŒã·ã¹ãæ€åºããããšãã§ããã æ¬çºæã«ãããã¢ãããŒã·ã¹ããŒã«ãŒã¯ãåèš ( a ) äž ( e ) ã®ããããã«èšèŒ ã®ããªãã¯ã¬ãªããããããã¯ãããã®ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããè çœè³ªã§ãããç¹å®ã®æ§é ãæããããªãã¯ã¬ãªãããèçœè³ªã枬å®ããæ¹æ³ã¯å
¬ç¥ ã§ãããããšãã°ãå¡©åºé
å·±åãæãããªããªãã¯ã¬ãªããã¯ãã€ããªãã€ãŒãŒã·ã§ ã³ã PCRãå©çšããããšã«ãã£ãŠã ãã®éã枬å®ããããšãã§ããã ãŸãã ã¡ãã é
žé
åãæãããªèçœè³ªã¯ããã®èçœè³ªãèªèããæäœãå©çšããã£ã ãã¢ãã»ã£
ã«ãã£ãŠæž¬å®ããããšãã§ãããæŽã«èçœè³ªãæããçååŠçãªæŽ»æ§ãææšãšããŠã èçœè³ªã®éã枬å®ããããšãã§ããã
ã¢ãããŒã·ã¹ããŒã«ãŒã®æž¬å®å€ã¯ãéåžžãå¥åžžè
ã®æž¬å®ã¬ãã«ãšæ¯èŒããããè€ æ°ã®å¥åžžè
ã®çäœè©Šæã«ã€ããŠã¢ãããŒã·ã¹ããŒã«ãŒã枬å®ããçµ±èšåŠçãªææ³ã« ãã£ãŠæšæºå€ãèšå®ããããšãã§ããã被æ€è
ã®æž¬å®å€ãæšæºå€ãè¶ãã ã«ã¯ã 該被æ€è
ã¯ã¢ãããŒã·ã¹ãæãããšå€å®ãããã
æ¬çºæã«ããã¢ãããŒã·ã¹ã®æ€åºæ¹æ³ã«ã¯ãå
¬ç¥ã®ã¢ãããŒã·ã¹ããŒã«ãŒãçµã¿ åãããããšãã§ãããè€æ°ã®ã¢ãããŒã·ã¹ãäžåäžãçµã¿åãããããšã«ãã£ãŠã ã¢ãããŒã·ã¹ã®æ€åºç²ŸåºŠã®åäžãæåŸ
ã§ãããå
¬ç¥ã®ã¢ãããŒã·ã¹ããŒã«ãŒãšã㊠ã¯ä»¥äžã®ããŒã«ãŒã瀺ãããšãã§ããã
caspaseãã¡ããªãŒ MTSéå
èœ
(ããšãã° aspase - 2/3/7/8/9) LDHãªãªãŒã¹
ATP DMã®æçå
æ¬çºæã®æ€åºæ¹æ³ã«ãããŠãçäœè©Šæãšã¯ãçäœããæ¡åãããããããè©Šæã çšããããšãã§ãããå
·äœçã«ã¯ãè¡æ¶²ãå°¿ã ãããã¯åçš®èåšã®çæ€è©Šæçã瀺 ãããšãã§ãããç¹ã«ãçæ€è©Šæã«ãããã¢ãããŒã·ã¹ããŒã«ãŒã®çºçŸã¬ãã«ã®äž æã¯ããã®çµç¹ã«ãããã¢ãããŒã·ã¹ã®èšŒæãšãªãã ãŸããè¡æ¶²äžã®ã¢ãããŒã·ã¹ ããŒã«äžã®ã¬ãã«ã®äžæã¯ã çäœå
ã«ãããã¢ãããŒã·ã¹ã®é²è¡ãåæ ããŠããã æ¬çºæã®ã¢ãããŒã·ã¹ã®æ€åºæ¹æ³ã«åºã¥ããŠãåçèçã®èšºææ¹æ³ãæäŸãããã æ¬çºæã®åçèçã®èšºææ¹æ³ã¯ã 次ã®å·¥çšãå«ãã
( 1 )æ¬çºæã®ã¢ãããŒã·ã¹ã®æ€åºæ¹æ³ã«ãã£ãŠãè现èãçäœè©ŠæãšããŠã¢ã ããŒã·ã¹ãæ€åºããå·¥çšã ããã³
( 2 ) å·¥çš ( 1 ) ã«ãããŠã¢ãããŒã·ã¹ãæ€åºãããå Žåã«ãåçèçãé²è¡ã ãŠãããšå€å®ããå·¥çš
ãŸãã ãé
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ãªãããŸãã¯ãã®çž è£éã«çžè£çãªå°ãªããšã 15ãã¯ã¬ãªãããå«ãããªãã¯ã¬ãªãããã«ã¯ãæ¬çºæ
ã®èçœè³ªã®çºçŸãæå¶ããããã®ã¢ã³ãã»ã³ã¹ããªãã¯ã¬ãªãããå«ãŸãããäžæ¹ã æ¬çºæã«ãããã¡ã³ãã»ã³ã¹ãšã¯ãé
åçªå·ïŒ 2ãŸãã¯é
åçªå·ïŒ 4ã«èšèœœã®ã¡ãã é
žé
åãæããèçœè³ªã®çºçŸãæå¶ããããªãã¯ã¬ãªãããæå³ãããå³ã¡ã ãã® ãããªæŽ»æ§ãæããã¢ã³ãã»ã³ã¹ã¯ã CREBã®è±ãªã³é
žåãæå¶ãã CREBã®è±ãªã³é
ž ã£ååå¿ã®é»å®³å€ã ãŸãã¯ãèšæ¶ ·ç¥çµå€æ§çŸæ£ã®æ²»çè¥ããã¯äºé²å€ãšããŠçšãã ããšãã§ããã
ã¢ã³ãã»ã³ã¹ããªãã¯ã¬ãªããã¯ã ã¢ã³ãã»ã³ã¹ DNAã§ãã¢ã³ãã»ã³ã¹ãªãªãŽã ã¯ã¬ãªããã§ãã£ãŠãããã ã¢ã³ãã»ã³ã¹ DNAã¯ã å°ãªããšã 15bp以äžã 奜ãŸãã 㯠100bPã ããã«å¥œãŸãã㯠500bp以äžã®éé·ãæããéåžžã 3000bp以å
ã奜ãŸãã 㯠2000bP以å
ã®éé·ãæããã 該ã¢ã³ãã»ã³ã¹ DNAãåç¬ãããã¯ã ã¬ãããŠã€/㬠ã¹ãã¿ã¿ãŒãã¢ãããŠã£ã«ã¹ãã¯ã¿ãŒçã®é©åœãªãã¿ã¿ãŒã«ã¢ã³ãã»ã³ã¹æ¹åã«æ· å
¥ããŠçšããããšãã§ãããã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯ãå°ãªããšã 1 0 bp以äžã éåžž 1 0 O bp以å
ã 奜ãŸãã㯠2 O bp以äžã 5 O bp以å
ã®éé·ãæããã 該ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªããã¯ãäŸãã°ãé
åçªå·ïŒ 1ãŸãã¯é
åçªå·ïŒ 3ã« èšèŒã®å¡©åºé
åæ
å ±ãåºã«ãã¹ãããã©ãšãŒãæ³ ïŒStein "Physicochemical properties of phosphorot ioate oligodeoxynucleotides. Nucleic Acids Res. 16: 3209 - 3221 (1988) ) çã«ãã調補ããããšãå¯èœã§ããã
ãã®ãããªã¢ã³ãã»ã³ã¹ã«ã¯ãé
åçªå·ïŒ 2ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
ž é
åãæããèçœè³ªã®ç°åžžã«èµ·å ããçŸæ£ã®éºäŒåæ²»çãžã®å¿çšãèãããããæ¬ çºæã®èçœè³ªã®ç°åžžã«ã¯ãèçœè³ªã®æ©èœç°åžžãçºçŸç°åžžãªã©ãå«ãŸãããéºäŒåæ²» çã«çšããå Žåã«ã¯ãäŸãã°ãã¬ãããŠã£ã«ã¹ãã¯ã¿ãŒãã¢ãããŠã£ã«ã¹ãã¯ã¿ãŒã ã¢ããé䌎ã¥ã£ã«ã¹ã¹ã¯ã¿äžçã®ã¥ã£ã«ã¹ã¹ã¯ã¿äžããªããœãŒã çã®éãŠã€ã«ã¹ ãã¿ã¿ãŒçãå©çšããŠã ex vivã ã in riraæ³çã«ããæ£è
ãžæäžããããšãã§ã ããå
·äœçã«ã¯ãèè¡æ§çŸæ£ã«ããçµç¹ã®é害ã«ãããŠã¯ã¢ãããŒã·ã¹ãéèŠãªã¹ ããããšãªã£ãŠãããåŸã£ãŠãè¡æµé害ãèµ·ãããçµç¹ã«ãããæ¬çºæã®èçœè³ªã® çºçŸãé»å®³ã§ããã°ã èè¡æ§çŸæ£ã«äŒŽãçµç¹æå·ã軜æžããããšãã§ããã
æ¬çºæã®ããªãã¯ã¬ãªãããŸãã¯ã¡ã³ãã»ã³ã¹ããªãã¯ã¬ãªããã¯ãéºäŒåæ²»ç ã«çšããå Žåã«ã¯ã äŸãã°ã ã¬ãããŠã€ã«ã¹ãã¯ã¿ãŒã ã¢ãããŠã€ã«ã¹ãã¯ã¿^"ã ã¢ããé䌎ãŠã£ã«ã¹ã¹ã¯ã¿ãŒçã®ãŠã£ã«ã¹ã¹ã¯ã¿ãŒããªããœãŒã çã®éãŠã£ã«ã¹ ã¹ã¯ã¿äžãªã©ãå©çšããŠã ex vivoæ³ã in 'raæ³ãªã©ã«ããæ£è
ãžæäžããããšã ã§ããã
æ¬çºæã¯ã ãŸããé
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åã«ãã£ãŠæ§æãããæå決 å®åºãèªèããæäœãæäŸãããé
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åã«ãã£ãŠæ§æ ãããæå決å®åºã«ã¯ãããšãã°é
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åããéžæãã ãã¢ããé
žé
åãããªãæå決å®åºãå«ãŸããã ãã®ã»ããé
åçªå·ïŒ 4ã«èšèŒã® ã¢ããé
žé
åã«ãããŠãé
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åãšããã«é£æ¥ããã¢ã ãé
žé
åãšã§æ§æãããæå決å®åºãèªèããæäœã¯ã æ¬çºæã®æäœã«å«ãŸããã æŽã«ãé
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åãããªãé åã«ãã£ãŠæ§æããããé
å çªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªã®ç«äœæ§é ãããªãæå決å®åºãèª èããæäœããæ¬çºæã«å«ãŸããã é
åçªå·ïŒ 6ã«èšèŒã®ã¢ããé
žé
åã¯ãæ¬çºæ è
ããèŠåºããæ°èŠéºäŒå AF06972ã«åºæã®ã¢ããé
žé
åã§ããã ãããã£ãŠã ã ã®é åãç¹ç°çã«èªèããããšãã§ããæ¬çºæã®æäœã¯ã AF06972ã«ãã£ãŠã³ãŒã ãããèçœè³ªã®æ€åºã粟補ã«æçšã§ ãã ã
æ¬çºæã®æäœã®åœ¢æ
ã«ã¯ç¹ã«å¶éã¯ãªããããªã¯ãäžãã«æäœãã¢ãã¯ããŒãã« æäœãŸãã¯æåçµåæ§ãæãããããã®äžéšãå«ãŸããã ãŸããå
šãŠã®ã¯ã©ã¹ã®æ äœãå«ãŸãããããã«ãæ¬çºæã®æäœã«ã¯ãããåæäœãªã©ã®ç¹æ®æäœãå«ãŸããã æ¬çºæã®æäœã¯ãããªã¯ããŒãã«æäœã®å Žåã«ã¯ãæ¬çºæã®èçœè³ªãŸãã¯éšåã¹ ãããã家å
ã«å
ç«ããããšã«ããåŸãããšãå¯èœã§ãã ïŒCurrent protocols in Molecular Biology edit. Ausubel et al. (1987) Publisn. John Wiley & Sons. Section 11. 12ã11. 13) ã äžæ¹ã ã¢ãã¯ããŒãã«æäœã®å Žåã«ã¯ã æ¬çºæã®èçœè³ª ãŸãã¯éšåã¹ããããçšããŠããŠã¹ãå
ç«ããèŸè现èãšéªšé«è
«çŽ°èã现èèåã ãããã€ããªããŒã现èã®äžããåŸãããšãã§ãã ïŒCurrent protocols in
Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 11. 4ãïŒ 11. 11) ã
æ¬çºæã®èçœè³ªã«çµåããæäœã¯ãæ¬çºæã®èçœè³ªã®ç²Ÿè£œã«å ããäŸãã°ã ãã ãèçœè³ªã®çºçŸç°åžžãæ§é ç°åžžã®æ€æ» ·蚺æã«å©çšããããšãèãããããå
·äœç ã«ã¯ãäŸãã°çµç¹ãè¡æ¶²ã ãŸãã¯çŽ°èçããèçœè³ªãæœåºãã ãŠã§ã¹ã¿ã³ãããã ã€ã³ã°ã å
ç«æ²éã ELISAçã®æ¹æ³ã«ããæ¬çºæã®èçœè³ªã®æ€åºãéããŠã çºçŸã æ§é ã®ç°åžžã®æç¡ãæ€æ» ·蚺æããããšãã§ããã
æ¬çºæã®èçœè³ªã«çµåããæäœã¯ãæ¬çºæã®èçœè³ªã«é¢é£ããçŸæ£ã®æ²»ççã®ç® çã«å©çšããããšãèãããããæäœãæ£è
ã®æ²»çç®çã§çšããå Žåã«ã¯ã ããæ äœãŸãã¯ããåæäœãå
ç«åæ§ã®å°ãªãç¹ã§å¥œãŸããã ããæäœã¯ãå
ç«ç³»ããã ã®ãã®ãšå
¥ãå ããã¥ã¹ (äŸ Î¯ ã ãFunctional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Mendez, M. J. et al. (1997) Nat. Genet. 15 : 146-156 J åç
§ïŒ ã«å
ç«ããããšã«ãã調補ãã ããšãã§ããã ãŸãã ããåæäœã¯ãã¢ãã¯ããŒãã«æäœã®è¶
å¯å€é åãçšããéº äŒåçµã¿æãã«ãã£ãŠèª¿è£œããããšãã§ããïŒMethods in Enzymology 203, 99 - 121 (1991) )ã
æ¬çºæã¯ã次ã®å·¥çšãå«ããåè£ç©è³ªã®ã¢ãããŒã·ã¹ãå¶åŸ¡ãã掻æ§ãæ€åºãã æ¹æ³ã«é¢ããã
( 1 ) 次㮠ïŒa ) ã ïŒd ) ã®ããããã«èšèŒã®èçœè³ªãçºçŸãã现èã«åè£ç©è³ª ãæ¥è§Šãããå·¥çšã
( a ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœ
( b ) é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªã㯠ã¬ãªãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããããªãã¯ã¬ ã©ããã«ãã£ãŠã³ãŒãããã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœ
( c ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ ããã¯è€æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ãããã³ ZãŸãã¯ä»å ããã¢ã ãé
žé
åãæãã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã
( d )é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãš 90%以äžã® ãã¢ããžäžãæããã¢ããé
žé
åãããªãã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœ çã«åçãªèçœè³ª
( 2 )ã¢ãããŒã·ã¹ãèªå°ãããæ¡ä»¶äžã§åèšçŽ°èãå¹é€ããåèšçŽ°èã®ã¢ãã äžã·ã¹ã枬å®ããå·¥çšã ããã³
( 3 ) å·¥çš ( 2 ) ã®æž¬å®çµæãææšãšããŠãåè£ç©è³ªã®ã¢ããäžã·ã¹ãæå¶ã 㟠ãã¯ä¿é²ãã掻æ§ãæ€åºããå·¥çšã
åèšæ€åºæ¹æ³ã«ãããŠã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªãšã¯ã察 象ãšãªãèçœè³ªãã¢ãããŒã·ã¹èªå°æŽ»æ§ãæã€ããšãèšããåœè©²æŽ»æ§ã¯å
ã«è¿°ã¹ã æ¹æ³ã«ãã確èªããããšãã§ããã
åèš ( a )ãïŒd ) ã®ããããã«èšèŒã®èçœè³ªãçºçŸãã现èãšããŠã¯ã æ¬çºæ ã®èçœè³ªã®çºçŸã«ããã¢ãããŒã·ã¹ãåŒãèµ·ãããã现èã§ããã°çæ žçŽ°èãŸã ã¯åæ žçŽ°èã®ãããããçšããããšãå¯èœã§ããã奜ãŸããã¯åç©çŽ°èãçšãããã äžã§ã PC12ã®ãããªç¥çµçŽ°èã奜ãŸããã
åèšæ€åºæ¹æ³ã«ãããŠãã¢ãããŒã·ã¹ãèªå°ãããæ¡ä»¶ãšã¯ãåèš ( a )ãïŒd ) ã®ããããã«èšèŒã®èçœè³ªã现èå
ã§çºçŸãããæ¡ä»¶ã§ãããæ¬çºæã®èçœè³ªã®çŽ° èäžã§ã®çºçŸã¯ã¢ãããŒã·ã¹ã«çŽçµããã®ã§ããã®ãŸãŸã§ã¯å¹ççãªã¹ã¯ãªãŒãã³ ã°ãæåŸ
ã§ããªããããã§ãå¶åŸ¡å¯èœãªããã¢ãŒã¿ãŒé
åã®äžæµã«æ¬çºæã®èçœè³ª ãã³ãŒãããéºäŒåãçµåãããçºçŸãã©ã¹ãããå©çšããããšãã§ãããå¶åŸ¡å¯ èœãªããã¢ãŒã¿ãŒãšããŠã¯ãäŸãã°ã¡ã¿ããã©ãã£ã³ããã¢ãŒã¿äžçã瀺ãããšã ã§ããããã®ãããªããã¢ãŒã¿ãŒã®å¶åŸ¡äžã«æ¬çºæã®æŽ»æ§åèçœè³ªãã³äžãããéº äŒåãçºçŸãããã©ã¹ããã现èã«åœ¢è³ªè»¢æããããã®ããã«ããŠåŸããã圢質転 æäœã¯ã ããã¢ãŒã¿ãŒã掻æ§ã£åãããæ¡ä»¶äžã§ã¢ãããŒã·ã¹ãåŒãèµ·ããããã
åèšçŽ°èã®ã¢ãããŒã·ã¹ã枬å®ããå·¥çšã§ã¯ã 现èã®åœ¢æ
ã®å€åã DNAã®æçå ãææšãšããŠæ€åºããæ¹æ³ãæ¡çšããããšãäžè¬çã§ãããã¢ããäžã·ã¹ã«ãã现 èã®åœ¢æ
åŠçãªå€åã¯ã ã®ã ã¶æè²ãèå
æè²ã®æè²åã®å€åãšããŠèŠ³å¯ãããã ããã㯠DNAã®æçåã¯ã Tè§ Læ³ïŒGavriel Y rt al, 1992 J Cell Biol, 119 :493 - 501) ã«ãã£ãŠæ€åºããããšãã§ããã ããã«ãåæã®ã¢ãããŒã·ã¹ãæ€åºããæ¹æ³ãšã ãŠã æ§é å€åãã现èèã«çµåããèå
æšè Annexin VãšãããŒãµã€ãã¡äžã¿ãŒã§ 枬å®ãã Annexin Væ³çãããïŒVermes I, et al. J Immunol Methods. 1995 Jul 17 ; 184(1) : 39-51. ) 0
åèšã¢ãããŒã·ã¹ãå¶åŸ¡ãã掻æ§ã®æ€åºæ¹æ³ã¯ãã¢ãããŒã·ã¹ãå¶åŸ¡ãã掻æ§ã æããç©è³ªã®è©äŸ¡ã«å©çšããããšãã§ããã ããªãã¡æ¬çºæã¯ã 次ã®å·¥çšãå«ãã ã¢ããäžã·ã¹ãå¶åŸ¡ãã掻æ§ãæããç©è³ªã®è©äŸ¡æ¹æ³ã«é¢ããã
( 1 )åèšæ€åºæ¹æ³ã«ãã£ãŠåè£ç©è³ªã®ã¢ãããŒã·ã¹ãæå¶ããŸãã¯ä¿é²ããæŽ»æ§ ãæ€åºããå·¥çšã ããã³
( 2 )察ç
§ãšæ¯èŒããŠãåèšçŽ°èã®ã¢ãããŒã·ã¹ãæå¶ã ãŸãã¯ä¿é²ãã掻æ§ãæ ããåè£ç©è³ªãéžæããå·¥çšã
ãããã¯æ¬çºæã¯ã次ã®å·¥çšãå«ãã䟯è£ç©è³ªã®ã¡ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ããã³ç¥çµçŽ°èã®å¢æ®ã®ãããããå¶åŸ¡ãã掻æ§ãæ€åºããæ¹æ³ã«é¢ããã
( 1 )åè£ç©è³ªã®ååšäžã é
åçªå·ïŒ 1ã ãŸãã¯ã é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãéºäŒåã®çºçŸå¶åŸ¡é åãšããã®äžæµã«æ©èœçã«çµåãããã¬ãäž ã¿äžéºäŒåãå«ããã¯ã¿äžãçºçŸãããå·¥çšã
( 2 ) åèšã¬ãäžã¿äžéºäŒåã®æŽ»æ§ã枬å®ããå·¥çšã ããã³
( 3 ) å·¥çš ( 2 ) ã®æž¬å®çµæãææšãšããŠãåè£ç©è³ªã®ã¢ãããŒã·ã¹ãç¥çµçŽ°è ã®ååã åãŽã ç¥çµçŽ°èã®å¢æ®ã®ãããããå¶åŸ¡ãã掻æ§ãæ€åºããå·¥çšã åèšæ€åºæ¹æ³ã«ãããŠãé
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åã ããªãéºäŒåã®çºçŸå¶åŸ¡é åã¯ã æè²äœ DNAããå
¬ç¥ã®æ¹æ³ã«ãã£ãŠã¯ããŒãŠã³ã° ããããšãã§ãããããšãã° S1ãããã³ã°æ³ã転åéå§ç¹ã®ç¹å®æ¹æ³ãšããŠå
¬ç¥ã§
ãã ïŒ ã転å調ç¯é åã®åé¢ã ããã³ ã転åå¶åŸ¡å åã®åå®ãšç²Ÿè£œã ã ã现èå·¥åŠ å¥å 8æ°çŽ°èå·¥åŠå®éšãããã³ãŒã«ã ãæ±äº¬å€§åŠå»ç§åŠç 究æå¶çç 究éšç·šç§æœ€ 瀟 1993幎ã 362-374) ã äžè¬ã«åœè©²éºäŒåã®çºçŸå¶åŸ¡é å DNAã¯ã ããæè²äœã©ã€ ãã©ãªãŒ ïŒgenomic library) ãã åœè©²éºäŒåã® 5'æ«ç«¯ã® 1 5ã1 0 O bpã 奜ãŸã ã㯠3 0ã5 0 bpããããŒã DNAã«çšããŠã¹ã¯ãªãŒãŠã³ã°ããããšã«ããã çºçŸå¶ 埡é åãå«ãéºäŒåã¯ããŒã³ãšããŠã¯ããŒãã³ã°ãããã
ãã®ããã«ããŠåŸãããã¯ããŒã³ã¯ãã°ãã° 1 O kbp以äžã®åœè©²éºäŒåã® 5'éç¿» èš³é åãå
å«ããŠãããããã§ã ãããã®ã¯ããŒã³ã® 5'æ«ç«¯ãã§ããœãã¯ã¬ã¢ãŒãŒ åŠçãªã©ã«ãã£ãŠççž®åããããã¯æçåãããççž®ãããçºçŸå¶åŸ¡é åãå«ãé
åã§ã¬ããŒã¿ãŒéºäŒåã®çºçŸã®åŒ·ããçºçŸã®å¶åŸ¡ã«ã€ããŠã®è©äŸ¡ãè¡ãããšã«ã ã€ãŠã çºçŸå¶åŸ¡é åã®æŽ»æ§ç¶æã®ããã®æå°å¿
èŠåäœãåŸãããšãã§ãã
(deletion study) 0
ãŸãã éºäŒåã®çºçŸå¶åŸ¡é åã Neural Network ãçšããŠäºæž¬ããããã°ã©ã ã å
¬ç¥ã§ãã (nttp:// ww. fruitf ly. org/ seq_tools/promoter. html, Reese, M. G.ïŒ et al, "Large Scale Sequencing Spesif ic Neural Networks for Promoter and Splice Site Recognition" Biocomputing: Proceedings of the 1996 Pacific Symposium, edited by Lawrence Hunter and Terri E. Klein , World Scientific Publishing Co, Singapore, January 2-7, 1996)ã ããã㯠Promoter Scanã®ãããªè»¢åå åçµ åé
åãæ€çŽ¢ããŠçºçŸå¶åŸ¡é åãäºæž¬ããããã°ã©ã ãçšã掻æ§ã®æå°åäœãäº æž¬ããããšãè¡ãããŠãã
(http://biosci. cbs. umn. e du/ s of twar e/ pros can/pr omot er s can. htm, Prestridge, D. S. 1995ïŒ Prediction of Pol II Promoter Sequence using Transcription Facter Binding Sites. J. Mol. Biol. 249ïŒ 923 - 932)ã ãŸãã äºæž¬ãããã³ã¢ã®éšåãäž å¿ã« deletion studyãå®æœããããšãã§ããã
ãã®ããã«ããŠåé¢ãããæ¬å¶åŸ¡é åéºäŒåã®äžæµã«ãã¬ããŒã¿ãŒéºäŒåãæ©èœ çã«çµåãããçºçŸãã¯ã¿ãŒã¯ã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ãããã¯ç¥çµçŽ°
èã®å¢æ®ãå¶åŸ¡ãã掻æ§ã®æ€åºã«çšããããšãã§ãããæ¬çºæã«ãããŠãæ©èœç㪠çµåãšã¯ãåèšçºçŸå¶åŸ¡é åã®æŽ»æ§ã£ãã«ãã£ãŠã ã¬ããŒã¿ãŒéºäŒåã®è»¢åãéå§ã ããããã«äž¡è
ãçµåããããšãæå³ããã ã¬ããŒã¿ãŒéºäŒåã«ã¯ãåèšçºçŸå¶åŸ¡ é åã®æŽ»æ§ã£åãéºäŒåã®çºçŸãšããŠèŠ³å¯ããããšãã§ããèçœè³ªãã³ãŒãããã ã®ã§ããã°ä»»æã®éºäŒåãå©çšããããšãã§ãããå
·äœçã«ã¯ãäŸãã°ã«ã·ãã§ã© ãŒãŒã ã«ã¿ã©ãŒãŒã ã¬ã©ã¯ãã·ãäžãŒã GFP (Green Fluorescent Protein) çã® éºäŒåãã¬ããŒã¿ãŒéºäŒåãšããŠäžè¬ã«çšããããããã¯ã¿ãŒãå°å
¥ãã现èã«ã¯ã äŸãã°åœè©²éºäŒåãæ¬ å€±ãããåç©çŽ°èãçšããããšãã§ããã
äžèšãã¯ã¿ãŒãå°å
¥ãã现èã¯ã现èæ» ïŒã¢ãããŒã·ã¹ïŒããŸãã¯çŽ°èã®ååã ããã¯å¢æ®ãåŒãèµ·ãããããªæ¡ä»¶äžã§ããã¢ãŒã¿ãŒã掻æ§åãããã¬ããŒã¿ãŒéº äŒåã«ããã·ã°ãã«ãçæãããåŸããã现èã 96ãŠã§ã«ãã«ããã¬ãŒãã«æçš®ãã ã¢ãããŒã·ã¹ããŸãã¯çŽ°èã®åã£åãããã¯å¢æ®ãåŒãèµ·ããæ¡ä»¶äžã§å¹é€ãéå§ã ãã ãã®ãšãè©äŸ¡ãã¹ãååç©ãåã¥ãšã«ã«å ããããšã«ãããåœè©²éºäŒåã®çºçŸ å¶åŸ¡é åã«äœçšããŠãçºçŸãæå¶ããããããã¯ä¿é²ãã掻æ§ãã¬ããŒã¿ãŒéºäŒå ãææšãšããŠå®¹æã«æ€åºããããšãã§ããã
äŸãã°ã ã¬ããŒã¿ãŒéºäŒåãšã㊠GFPãçšããå Žåã 䟯è£ç©è³ªãå ããç¶æ
ãã å ããªãå Žåã§ã® GFPã®çºå
éã®æ¯èŒãè¡ãããšã«ããã çºçŸå¶åŸ¡é åã«å¯Ÿãã 圱é¿ãè©äŸ¡ããããšãã§ãããæ¯èŒã«ããã£ãŠã¯ãããšãã° 2å以äžè¥ãã㯠1 / 2以äžã奜ãŸãã㯠5åè¥ãã㯠1 5以äžã ãã奜ãŸãã㯠1 0å以äžè¥ãã㯠1 / 1 0以äžã®çºå
éæ¯ã瀺ã^ ãã ææãªå·®ããããšå€å®ããããšãã§ããã æ¬æ¹æ³ã¯åç©çŽ°èã°ããã§ãªãåæ§ãªã·ã¹ãã ã§çŽ°èæ»ããŸãã¯çŽ°èã®ååããã ã¯å¢æ®ãåŒãèµ·ãããããªå®¿äž»ã§ããã°ãçæ žçç© Â·åæ žçç©ãåããå¿çšããã ãšãã§ããããã®ãšãã现èã¯ã¬ããŒã¿ãŒéºäŒåãçºçŸå¯èœãªæ¡ä»¶äžã§å¹é€ãããã ãŸãã ã¬ããŒã¿ãŒéºäŒåãå«ãåèšçºçŸãã¯ã¿ãŒã¯ã Ï Ï 'ίÎÎã®å®éšç³»ã«ãã㊠çšããããšãã§ããã ããªãã¡ã i 'iroèçœè³ªåæã«å¿
èŠãšãããç¡çŽ°èæœåºæ¶² ã«ã æ¬çºçŸãã¯ã¿ãŒãšãšãã«ã ç·©è¡æ¶²ã ã¢ããé
žã ãšãã«ã®ãŒæºã§ãã ATPããã³
GTPãäŸçµŠãã 䟯è£ç©è³ªã«ããã¬ããŒã¿ãŒéºäŒåã®çºçŸã®é»å®³ãŸãã¯ä¿é²ãæ€å®ã ãããšãã§ãããæ¬æ¹æ³ã§çšããç¡çŽ°èæœåºæ¶²ãšããŠã¯ãåç©ç¥çµçŽ°èãšåæ§ãªã· ã¹ãã ã«ãã现èæ»ããŸãã¯ã现èã®ååãããã¯å¢æ®ãåŒãèµ·ãããããªå®¿äž»ç± æ¥ã®ãã®ãçšããããšãã§ããã
ããã§ãã¢ãããŒã·ã¹ãåŒãèµ·ãããããªæ¡ä»¶ã现èã®åã£åãããã¯å¢æ®ãåŒã èµ·ãããããªæ¡ä»¶ãšã¯ãåèšçºçŸå¶åŸ¡é åããã®æ什ã«ããã¬ãäžã¿ãŒéºäŒåã®çº çŸãèªå°ãããæ¡ä»¶ãèšãã
åèšã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååãããã³ç¥çµçŽ°èã®å¢æ®ã®ãããããå¶åŸ¡ã ã掻æ§ã®æ€åºæ¹æ³ã¯ã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ããã³ç¥çµçŽ°èã®å¢æ®ã®ã ããããå¶åŸ¡ãã掻æ§ãæããç©è³ªã®è©äŸ¡ã«å©çšããããšãã§ãããããªãã¡æ¬çº æã¯ã次ã®å·¥çšãå«ãã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ããã³ç¥çµçŽ°èã®å¢æ®ã® ãããããå¶åŸ¡ãã掻æ§ãæããç©è³ªã®è©äŸ¡æ¹æ³ã«é¢ããã
( 1 ) åèšæ€åºæ¹æ³ã«ãã£ãŠãåè£ç©è³ªã®ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ãã ãŽç¥çµçŽ°èã®å¢æ®ã®ãããããæå¶ã ãŸãã¯ä¿é²ãã掻æ§ãæ€åºããå·¥çšã 䞊ã³ã«
( 2 ) 察ç
§ãšæ¯èŒããŠã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååã ããã³ç¥çµçŽ°èã®å¢æ® ã®ãããããæå¶ã ãŸãã¯ä¿é²ãã掻æ§ãæããåè£ç©è³ªãéžæããå·¥çšã ã«ãããŠãæ¬çºæã¯æ¬¡ã®å·¥çšãå«ããåè£ç©è³ªã®ç¥çµçŽ°èã®ååããã³/ãŸãã¯å¢ æ®ãå¶åŸ¡ãã掻æ§ã®æ€åºæ¹æ³ã«é¢ããã
( 1 ) 次㮠ïŒa ) ã ïŒd ) ã®ããããã«èšèŒã®èçœè³ªãçºçŸãã现èã«åè£ç©è³ªã æ¥è§Šãããå·¥çšã
( a )é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªã
( b )é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ æãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããããªãã¯ã¬ãªã ãã«ãã£ãŠã³ãŒãããã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã
( c ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ã
ãã¯è€æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ãããã³ ZãŸãã¯ä»å ããã¢ããé
ž é
åãæãã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªã
( d ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãš 90%以äžã®ã ã¢ããžäžãæããã¢ããé
žé
åãããªãã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã« åçãªèçœè³ª
( 2 )ç¥çµçªèµ·ã®äŒžå±ãèªå°ãããæ¡ä»¶äžã§åèšçŽ°èãå¹é€ããåèšçŽ°èã®ç¥çµçª èµ·ã®äŒžå±ã枬å®ããå·¥çšã ããã³
( 3 ) å·¥çš ( 2 ) ã®æž¬å®çµæãææšãšããŠãåè£ç©è³ªã®ç¥çµçŽ°èã®ååããã³/㟠ãã¯å¢æ®ãæå¶ã ãŸãã¯ä¿é²ãã掻æ§ãæ€åºããå·¥çšã
åèšæ€åºæ¹æ³ã«ãããŠã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªãšã¯ã察 象ãšãªãèçœè³ªãç¥çµçŽ°èã®ååãã㎠ZãŸãã¯å¢æ®æŽ»æ§ãæã€ããšãèšããåœè©² 掻æ§ã¯ãç¥çµçŽ°èã®åã£åããã³ ZãŸãã¯å¢æ®ãææšãšããŠè¡ããããäŸãã°ã PC12 现èçã®ç¥çµçŽ°èã«ãããç¥çµçªèµ·äŒžå±äœçšãæ€åºããããšã«ããè¡ãããšã㧠ããã
åèšæ€åºæ¹æ³ã¯ã äŸãã°æ¬¡ã®ããã«ããŠå®æœããããšãã§ããã HJ06972éºäŒå è¥ãã㯠AF06972ã«ããã³ãŒããããèçœè³ªã ãŸãã¯è©²èçœè³ªãšæ©èœçã«åçãªè çœè³ªãçºçŸããããã«äœæããã PC12çã®çŽ°èã«å¯Ÿãåè£ç©è³ªãæ¥è§Šãããããã® ãšãã现èãå¯èŠã£åã§ããèçœè³ªãçºçŸãããããã«åœ¢è³ªè»¢æãã现èãçšãã㚠芳å¯ã容æãšãªãã ãã®ãããªèçœè³ªãšããŠã¯ã GFPãçšããããšãã§ããã ãã® åŸãç¥çµçŽ°èã®æ°ãååã®å€ã£ãã芳å¯ããããšã«ããã ç®çãšãã掻æ§ãæ€åºãã ããšãã§ããã现èã®ååã¯ç¥çµçªèµ·ã®é²å±ãªã©ãææšãšããŠè©äŸ¡ããããšãã§ã ãã
åèš ( a )ãïŒd ) ã®ããããã«èšèŒã®èçœè³ªãçºçŸãã现èãšããŠã¯ãæ¬çºæ ã®èçœè³ªã®çºçŸã«ããååãã㎠ZãŸãã¯å¢æ®ãåŒãèµ·ããããç¥çµçŽ°èã§ãã ã°ãããã®çŽ°èãçšããããšãå¯èœã§ããã奜ãŸãã㯠PC12çã®ã¯ããŒã³åããã ç¥çµçŽ°èæ ªãçšããããã
åèšæ€åºæ¹æ³ã«ãããŠãç¥çµçªèµ·ã®äŒžå±ãèªå°ãããæ¡ä»¶ãšã¯ãåæŸ 3 ( a )ãïŒ d ) ã®ããããã«èšèŒã®èçœè³ªã现èå
ã§çºçŸãããæ¡ä»¶ã§ããã
åèšç¥çµçŽ°èã®ååãã㎠ZãŸãã¯å¢æ®ãå¶åŸ¡ãã掻æ§ã®æ€åºæ¹æ³ã¯ãç¥çµçŽ°è ã®åã£åããã³/ãŸãã¯å¢æ®ãå¶åŸ¡ãã掻æ§ãæããç©è³ªã®è©äŸ¡ã«å©çšããããšã ã§ãããããªãã¡æ¬çºæã¯ã次ã®å·¥çšãå«ããç¥çµçŽ°èã®ååãã㎠ZãŸãã¯å¢æ® ãå¶åŸ¡ãã掻æ§ãæããç©è³ªã®è©äŸ¡æ¹æ³ã«é¢ããã
( 1 )åèšæ€åºæ¹æ³ã«ãã£ãŠåè£ç©è³ªã®ç¥çµçŽ°èã®åã£åããã³ ZãŸãã¯å¢æ®ãå¶ åŸ¡ãã掻æ§ãæ€åºããå·¥çšã 䞊ã³ã«
( 2 )察ç
§ãšæ¯èŒããŠãç¥çµçŽ°èã®ååãã㎠ZãŸãã¯å¢æ®ãå¶åŸ¡ãã掻æ§ãæ ããåè£ç©è³ªãéžæããå·¥çšã
æ¬çºæã®è©äŸ¡æ¹æ³ã«çšããåè£ç©è³ªã¯ç¹ã«å¶éãããªããå
·äœçã«ã¯ãããšã㰠现èæœåºæ¶²ã éºäŒåã©ã€ãã©ãªãŒã®çºçŸç£ç©ã åæäœååååç©ã åæããããã 倩ç¶ååç©çãæããããã ãããã¯ã åèš ïŒa ) ã ïŒd ) ã®ããããã«èšèŒã®è çœè³ªãèªèããæäœããã¹ã¯ãªãŒãã³ã°ã«çšããåè£ç©è³ªãšããŠæçšã§ãããäžæ¹ã æ¬çºæã®è©äŸ¡æ¹æ³ã«ããã察ç
§ã«ã¯ãæ¬çºæã®èçœè³ªã®æ©èœããŸãã¯çºçŸã¬ãã«ã« 圱é¿ãäžãã ïŒãããã¯äžããªãïŒ ããšãå€æããŠããååç©ãçšããããšãã§ã ãã
æŽã«ãæ¬çºæã«ãããèçœè³ªã®æŽ»æ§ã調ç¯ãã掻æ§ã®æ€åºæ¹æ³ã«ã¯ãæ©èœçã«å çãªèçœè³ªãå©çšããããšãã§ããã ããšãã°ã HJ06972ã«å¯Ÿã㊠AF06972ã¯ã ã¢ã ãé
žé
åã¬ãã«ã§çŽ 90%ã®çžåæ§ãåããŠããã ãã®ããšã¯ããããã®èçœè³ªãš 90% 以äžã®çžåæ§ãæããã¢ããé
žé
åãããªãèçœè³ªããããããåæ§ã®æŽ»æ§ãæã ãŠããããšãè£ä»ããŠããã ãããã£ãŠãé
åçªå·ïŒ 2ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒ ã®ã¢ããé
žé
åã«å¯ŸããŠã 90%以äžã®çžåæ§ãæããã¢ããé
žé
åãããªãèçœè³ª ã¯ãæ¬çºæã«ãã掻æ§ã®æ€åºæ¹æ³ã«ãããŠã奜ãŸããèçœè³ªãšããŠçšããããšã㧠ããããŸãåæ§ã«ããã€ããªãã€ãºãã¡ããé
žã®çœ®æã«ãã€ãŠåŸãããšãã§ããæ© èœçã«åçãªèçœè³ªãã äžèšæŽ»æ§ã®æ€åºæ¹æ³ã«çšããããšãã§ããã
æ¬çºæã®è©äŸ¡æ¹æ³ã¯ã ç®çãšãã掻æ§ãæããååç©ã®ã¹ã¯ãªãŒãã³ã°æ¹æ³ãã ååç©ã®ãã£ã©ã¯ã¿ãªãŒãŒã·ã§ã³çã«å©çšããããšãã§ãããããšãã°ãå¹
åºãç© è³ªã«å¯ŸããŠæ¬çºæã«åºã¥ãè©äŸ¡æ¹æ³ãå®æœããç®çãšãã掻æ§ã«åªããååç©ã®éž æãç¹°ãè¿ãããšã«ãããã¹ã¯ãªãŒãã³ã°ãå®æœããããšãã§ããã ãããã¯ãå èšæ€åºæ¹æ³ãå©çšããŠã ç¹å®ã®ååç©ã®ç¹æ§ã解æããããšãã§ããã
ãã®è©äŸ¡ã«ããåé¢ãããååç©ã¯ãæ¬çºæã®èçœè³ªã®æŽ»æ§ããããã¯ãã®çºçŸ ãä¿é²ãŸãã¯é»å®³ããååç©ïŒã¡ãŽãã¹ããã¢ã³ã¿ãŽãã¹ãïŒã®åè£ãšãªãããŸãã çäœå
ã«ãããŠãæ¬çºæã®èçœè³ªãšãããšçžäºäœçšããååãšã®è©²çžäºäœçšãé»å®³ ããååç©ã®åè£ãšãªãã ãããååç©ã¯ãæ¬çºæã®èçœè³ªãé¢é£ããçŸæ£ã®äºé² ãæ²»çã®ããã®å»è¬åãšããŠå¿çšãèããããã
æŽã«æ¬çºæã¯ãæ¬çºæã®è©äŸ¡æ¹æ³ã«ãã£ãŠåŸãããšãã§ããç©è³ªã®å»è¬çšéã«é¢ ãããããªãã¡æ¬çºæã¯ãåèšè©äŸ¡æ¹æ³ã«ãã£ãŠéžæãããååç©ã®ã现èæ»ã®å¶ 埡ã«ããã䜿çšã«é¢ããã ãããã¯æ¬çºæã¯ã ãããã®ååç©ãäž»æåãšããŠå«æ ããããšãç¹åŸŽãšããã现èæ»ã«ç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã«é¢ãããæŽã«æ¬çº æã¯ãåèšè©äŸ¡æ¹æ³ã«ãã£ãŠéžæãããã£ååç©ãæäžããå·¥çšãå«ãã现èæ»ã®å¶ 埡æ¹æ³ã«é¢ãããå ããŠæ¬çºæã¯ãåèšè©äŸ¡æ¹æ³ã«ãã£ãŠéžæãããååç©ã®ã现 èæ»ã«ç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã®è£œé ã«ããã䜿çšã«é¢ããã
æ¬çºæã«ãããŠçŽ°èæ»ã«ç¹åŸŽä»ããããçŸæ£ãšã¯ãç°åžžãªçŽ°èæ»ã«ãã£ãŠããã ãããçŸæ£ãæå³ãããããšãã°çŽ°èæ»ã«ãã€ãŠããããããçŸæ£ãšããŠã¯ãè³è è¡ã«ãã£ãŠããããããè³çµç¹é害ãªã©ã瀺ãããšãã§ãããæ¬çºæã®ã¢ãããŒã· ã¹é¢é£å åã®æ©èœãç£çãã®ãã®ãé»å®³ããååç©ã¯ã次ã®ãããªçŽ°èæ»ã®å¶åŸ¡ã« å©çšããããšãã§ããã
( 1 ) èè¡ã«ãã现èæ»
( 2 ) æ
¢æ§ãŠã£ã«ã¹æ§çŸæ£ã«ããã现èæ»ã ãããã¯
ä»ã®ç
å埮çç©ã«ããæ
¢æ§çŸæ£ã«ããã现èæ»
( 3 ) èªå·±å
ç«åå¿ã«ããççãšããã«äŒŽã现èæ»
(4) åå äžæã ã现èæ»ãšããã«äŒŽãå€æ§ã«ããçŸæ£ ïŒã¢ã«ããã€ããŒçïŒ ãããã®çŽ°èæ»ã¯ãäŸãã°æ¬¡ã®ãããªçŸæ£ã«ãã£ãŠãããããããåŸã£ãŠãæ¬çº æã®è©äŸ¡æ¹æ³ã«ãã€ãŠéžæãããååç©ã¯ã次ã®ãããªçŸæ£ã®æ²»çã«çšããããšã ã§ããã
è³è¡ç®¡é害æ§çŽåã å€çºæ§åŸ®å°è³æ¢å¡ãè³è¡æ çãè³æ¢å¡ãè³åºè¡ã å¿çæ¢å¡ã å¿ ççã ãŠã£ã«ã¹æ§èçã ã¢ã«ã³ãŒã«æ§èçãè硬å€ã ã€ã³ã¹ãªã³äŸåæ§ç³å°¿ç
èã©ã³ã²ã«ãã³ã¹å³¶çŽ°èã®å
ç«åå¿æ§çŽ°èæ»ã«ããïŒ
ãã®ä»ãæ¬çºæã«ãã€ãŠéžæãããååç©ãçœè¡ç
ãªã©ã®çã®æ²»çã«çšããããš ãã§ãããçã¯ãæªæ§è
«ç现èã«ããã现èæ»ã®å¶åŸ¡ãäžå®å
šãªç
æ
ã§ããã ãã ãã£ãŠãæ¬çºæã«ãã£ãŠéžæãããååç©ã®æäžã«ãã£ãŠãæªæ§è
«ç现èã®çŽ°èæ» ãèªå°ããããšãã§ããã°ã æ²»çå¹æãæåŸ
ã§ããã
ãããã¯æ¬çºæã¯ãåèšè©äŸ¡æ¹æ³ã«ãã£ãŠåŸãããšãã§ããååç©ãäž»æåãšã ãŠå«æããã现èååã ãŸãã¯å¢æ®ã®å¶åŸ¡ã«ããã䜿çšã«é¢ããã ãããã¯æ¬çºæ ã¯ã ãããã®ååç©ãäž»æåãšããŠå«æããããšãç¹åŸŽãšããã现èååããŸã㯠å¢æ®ã«ç¹åŸŽä»ããããçŸæ£ã®æ²»,ã«é¢ãããæŽã«æ¬çºæã¯ãåèšè©äŸ¡æ¹æ³ã«ã〠ãŠéžæãããååç©ãæäžããå·¥çšãå«ãã现èã®ååãŸãã¯å¢æ®ã®å¶åŸ¡æ¹æ³ã«é¢ ãããå ããŠæ¬çºæã¯ãåèšè©äŸ¡æ¹æ³ã«ãã£ãŠéžæãããååç©ã®ã现èã®åå㟠ãã¯å¢æ®ã«ç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã®è£œé ã«ããã䜿çšã«é¢ããã
æ¬çºæã«ãããŠçŽ°èã®ååãŸãã¯å¢æ®ã«ç¹åŸŽä»ããããçŸæ£ãšã¯ã现èååãå¢ æ®ãäžå
åãªããšã«ãã£ãŠããããããçŸæ£ãæå³ããã现èã®ååããããã¯å¢ æ®ãäžå
åãªããšã«ãã£ãŠããããããçŸæ£ãšããŠã¯ãããšãã°ã¢ã«ããã€ããŒã« 代衚ãããç¥çµå€æ§çŸæ£çã瀺ãããšãã§ããã ãã®ä»ãçš®ã
ã®åå ã«ãã£ãŠçã ãçµç¹ã®é害ãå®å
šã«ä¿®åŸ©ãããªãç¶æ
ãã现èã®ååããããã¯å¢æ®ãäžå
å㪠ããšã«ããç
æ
ãšèšãããšãã§ããã ããå
·äœçã«ã¯ãè³æ¢å¡ãè³èè¡ã®çµæãã ããããç¥çµ m ã®é害ã®ä¿®åŸ©ãäžå®å
šãªç¶æ
ã¯ãç¥çµå€æ§çŸæ£ã«å«ãŸãããæ¬çº æã«åºã¥ããŠãååããŸãã¯å¢æ®ãèªå°ãã¹ã现èãšããŠã¯ãç¥çµçŽ°èãæãŸããã
æ¬çºæã«ãã€ãŠéžæãããååç©ã¯ã现èæ»ãšã现èã®ååãããã¯å¢æ®ãšããã ç°ãªãäœçšãæãããæ¢ã«è¿°ã¹ãããã«ãæ¬çºæã®è©äŸ¡æ¹æ³ã«ãããŠæšçãšããå åã§ãã HJ06972ããã㯠AF06972ã¯ããããã现èæ»ãšçŽ°èã®ååãããã¯å¢æ®ãš ãã 2é¢çãªæ©èœãæããŠããã ãããã£ãŠãã®æŽ»æ§ãçºçŸã調ç¯ããååç©ãã 2é¢çãªäœçšãæããå¯èœæ§ã¯ããã ããããªãããç¹å®ã®ç
æ
ã«ãããŠãé©å㪠ååç©ãæäžããã°ã ãããã®ã£ååç©ããæ§ã
ãªçŸæ£ã®æ²»çã«å©çšããããšãå¯èœ ã§ããããšã¯èšããŸã§ãç¡ãã
æŽã«æ¬çºæã¯ã äžèšã® ïŒa ) ã ïŒg ) ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã 㟠ãã¯ãã®ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªãäž»æåãšããŠå«æããã 现èå¢æ®ã现èååããŸãã¯çŽ°èæ»ã«ãã€ãŠç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã«é¢ããã
( a ) é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ ã©ãã
( b ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãã³ãŒãããã ãªãã¯ã¬ãªããã
( c ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ã ãã¯è€æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ãããã³/ãŸãã¯ä»å ããã¢ããé
ž é
åãæãã ïŒa ) ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããã ãªãã¯ã¬ãªããã
( d ) é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªãããªãã¯ã¬ ã©ãããšã¹ããªã³ãžã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºããé
åçªå·ïŒ 2ã 㟠ãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªè çœè³ªãã³ãŒãããããªãã¯ã¬ãªããã
( e ) é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãš 90%以äžã®ãã¢å£ ãžãŒãæããå¡©åºé
åãããªããé
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒ ã®ã¢ããé
žé
åãããªãèçœè³ªãšæ©èœçã«åçãªèçœè³ªãã³ãŒãããã㪠ãã¯ã¬ãªããã
( f ) ( a ) ã ïŒe ) ã«èšèŒã®ããªãã¯ã¬ãªããã®ã¢ã³ãã»ã³ã¹ããªãã¯ã¬ãªã ããã
( g ) é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
žé
åã«ãããŠã 1è¥ ããã¯æ°åã®ã¢ããé
žã眮æãæ¬ å€±ãæ¿å
¥ã ããã³/ãŸãã¯ä»å ããã¡ãã é
žé
åãããªããé
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
å ãããªãèçœè³ªã«å¯ŸããŠãããã³ããã¬ãã£ãã®åœ¢è³ªãæã€èçœè³ªãã³ãŒ ãããããªãã¯ã¬ãªããã
æ¬çºæã®æ²»çå€ã¯ã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®å¢æ®ã ããã³ç¥çµçŽ°èã®ååãã éžæãããããããã®çŸè±¡ã«ãã£ãŠç¹åŸŽä»ããããçŸæ£ã®æ²»çã«çšãããããæŽã« æ¬çºæã¯ã åèš ( a ) ã ïŒg ) ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããã ãŸãã¯ãã® ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªãæäžããå·¥çšãå«ããã¢ãããŒã· ã¹ãç¥çµçŽ°èã®å¢æ®ãããã³ç¥çµçŽ°èã®ååããéžæãããããããã®çŸè±¡ã«ã〠ãŠç¹åŸŽä»ããããçŸæ£ã®æ²»çæ¹æ³ã«é¢ããã å ããŠæ¬çºæã¯ã åèš ïŒa ) ã ïŒg ) ã®ããããã«èšèŒã®ããªãã¯ã¬ãªããããŸãã¯ãã®ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒ ããããèçœè³ªãã®ã ã¢ãããŒã·ã¹ãç¥çµçŽ°èã®å¢æ®ãããã³ç¥çµçŽ°èã®ååãã éžæãããããããã®çŸè±¡ã«ãã£ãŠç¹åŸŽä»ããããçŸæ£ã®æ²»çå€ã®è£œé ã«ããã 䜿çšã«é¢ããã
æ¬çºæã®èçœè³ªããã¯ã¬ãªãããæäœããã³äžèšè©äŸ¡æ¹æ³ã«ããåé¢ãããç©è³ª ã¯ãã¢ãããŒã·ã¹ã现èååããŸãã¯çŽ°èå¢æ®ã調ç¯ããããã«æçšã§ããããŸãã æ¬çºæã«ãããŠããããå»è¬åãšããŠçšããå Žåã«ã¯ãããèªäœãå»è¬åãšããŠçš ããããšãå¯èœã§ããããå
¬ç¥ã®è£œå€åŠçæ¹æ³ã«ãã補å€åããŠçšããããšãå¯èœ ã§ããã äŸãã°ãè¬çåŠäžèš±å®¹ãããæ
äœãããã¯åªäœãå
·äœçã«ã¯ãæ»
èæ°Žãç çé£å¡©æ°Žãæ€ç©æ²¹ãä¹³åå€ãæžæ¿å€ãªã©ãšé©å®çµã¿åãããŠè£œå€åããŠçšããããš ãèããããã
æ£è
ãžã®æäžã¯ãäŸãã°ãåèå
泚å°ã éèå
泚å°ã ç®äžæ³šå°çã åœæ¥è
ã«å
¬ç¥ ã®æ¹æ³ã«ããè¡ãåŸããæäžéã¯ãæ£è
ã®äœéã幎霢ãæäžæ¹æ³çã«ããå€åãã
ãã åœæ¥è
ã§ããã°é©åœãªæäžéãé©å®éžæããããšãã§ããã ãŸãã該ååç©ã DNAã«ããã³ãŒãããåŸããã®ã§ããã°ã 該 DNAãéºäŒåæ²»ççšãã¯ã¿ãŒã«çµèŸŒã¿ã éºäŒåæ²»çãè¡ãããšãèããããã
æäžéãæäžæ¹æ³ã¯ãæ£è
ã®äœéã幎霢ãçç¶çã«ããå€åããã åœæ¥è
ã§ãã ã°ã å¿
èŠã«å¿ããŠæäžéãæäžæ¹æ³ãé©å®éžæããããšãã§ããã
ããã«æ¬çºæã¯ã以äžã®ïŒ a )ãïŒ d )ã®ããããã«èšèŒã®èçœè³ªã®çºçŸã調ç¯ãã ãã©ã³ã¹ãžãšããã¯éããåç©ãããªããã¢ãããŒã·ã¹ãç¥çµçŽ°èã®ååãããã³ ç¥çµçŽ°èã®å¢æ®ã調ç¯ãããã¢ãã«åç©ã«é¢ããã
( a )é
åçªå·ïŒ 2ã ãŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
žé
åãããªãèçœè³ª
( b )é
åçªå·ïŒ 1ã ãŸãã¯é
åçªå·ïŒ 3ã«èšèŒã®å¡©åºé
åãããªã DNAãšã¹ããªã³ãž ã§ã³ããªæ¡ä»¶äžã§ãã€ããªãã€ãºãã DNAã«ãã£ãŠã³ãŒããããïŒa )ã«èšèŒã® èçœè³ªãšæ©èœçã«åçãªèçœè³ª
( c )é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¢ããé
žé
åã«ãã㊠1è¥ããã¯è€ æ°ã®ã¢ããé
žã眮æãæ¬ å€±ãæ·å
¥ãããã³ ZãŸãã¯ä»å ããã¢ããé
žé
åãæ ãã ïŒa )ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªèçœè³ª
( d )é
åçªå·ïŒ 2ããŸãã¯é
åçªå·ïŒ 4ã«èšèŒã®ã¡ããé
žé
åãš 9 0 %以äžã®ãã¢å£ ãžãŒãæããã¡ããé
žé
åãããªããïŒ a )ã«èšèŒã®èçœè³ªãšæ©èœçã«åçãªè ããšãã°æ¬çºæã®èçœè³ªãéå°çºçŸããããã©ã³ã¹ãžã§ããã¯åç©ã¯ãç¥çµå€æ§ çŸæ£ãèªå°ããã¢ãã«åç©ãšããŠãç¥çµå€æ§çŸæ£ã®æ²»çè¬ã®è©äŸ¡ã«çšããããšã㧠ããã å³é¢ã®ç°¡åãªèª¬æ
å³ 1ã¯ãããŠã¹ããã·ã³ãããŒãŒ MTYKãš HJ06972ã«ããã³ãŒããããèçœè³ªã®æ§ é ãæ¯èŒããå³ã§ããã MTYKã¯ã Apoptosis Associated Tyrosine Kinaseã®ç¥èª ã§ããã
å³ 2ã¯ã HJ06972éºäŒåã ãããŽè©²éºäŒåã«ã³ãŒããããèçœè³ª ïŒé
åçªå·ïŒ 2 ) ãšã ãã® alternative splicing formã§ãã AF06972éºäŒåã ãããŽè©²éºäŒåã«ã³ãŒ ããããèçœè³ª ïŒé
åçªå·ïŒ 4 ) ã®æ§é ãæ¯èŒããå³ã§ããã
å³ 3ã¯ã HJ06972éºäŒåã ããã³è©²éºäŒåã«ã³ãŒããããèçœè³ªãšã ãã® alternative splicing formã§ãã AF06972éºäŒåã ãããŽè©²éºäŒåã«ã³ãŒãããã èçœè³ªã®é
åãæ¯èŒããå³ã§ããã
å³ 4ã¯ã HJ06972éºäŒåã ããã³è©²éºäŒåã«ã³ãŒããããèçœè³ªãšã ãã® alternative splicing formã§ãã AF06972éºäŒåã ãããŽè©²éºäŒåã«ã³ãŒãããã èçœè³ªã®é
åãæ¯èŒããå³ã§ãã ïŒå³ 3ã®ç¶ãïŒ ã
å³ 5ã¯ã HJ06972éºäŒåãš AF06972éºäŒåã®å皮现èã«ãããçºçŸã¬ãã«ãæ¯èŒã ãçµæã瀺ãå³ã§ããã
å³ 6ã¯ã PC12现èãžã® HJ06972éºäŒåå°å
¥ã«ããç¥çµçªèµ·äŒžå±äœçšã瀺ãåç㧠ããã
å³ 7ã¯ã PC12现èãžã®åçš®éºäŒåã®ç¥çµçªèµ·äŒžå±äœçšãæ¯èŒãããã©ãã§ããã å³äžã 瞊軞ã¯ã ç¥çµçŽ°èã®äŒžå±ç (ïŒ
of neurite outgrowth)ãã 暪軞ã¯å°å
¥ããéº äŒåã瀺ãã
å³ 8ã¯ã HJ06972éºäŒåã® CREBã®è»¢å掻æ§ã«å¯Ÿããäœçšã瀺ãã°ã©ãã§ããã å³ äžã 瞊軞ã¯å¯Ÿç
§ã 1ãšããçžå¯Ÿç㪠CREB転å掻æ§ïŒçïŒ ãã暪軞ã¯å°å
¥ããéºäŒå ã瀺ãã
å³ 9ã¯ã Jurkat现èã«ãããåçš®éºäŒåå°å
¥ã«ããã¢ããäžã·ã¹èªå°äœçšã解æ ããçµæã瀺ããã©ãã§ããã 瞊軞ã¯ã¢ãããŒã·ã¹ãèµ·ããã现èã®å²å (%)ãã 暪軞㯠Jurkat现èã«å°å
¥ããéºäŒåã瀺ãã ã°ã©ãã®å³åŽã Thapsigargin ( 1ã M) ãæ·»å ãããšãã ãããŠå·ŠåŽãç¡æ·»å ã®å Žåã®çµæã§ããã
å³ 1 0ã¯ãããŠã¹ Ba/F3现èã® IL - 3ã®æ¯æžŽã«ãã£ãŠèªå°ãããã¢ãããŒã·ã¹ã«äŒŽ ãã ããŠã¹ããã·ã³ãããŒãŒ MTYKãš mAF06972ã®çºçŸã¬ãã«ã®å€åã瀺ãåçã§ã ãã Mã¯ååéããŒã«ãŒãããŸã 0â 4 8㯠IL-3ãé€å»åŸã®çµéæéã瀺ããŠããã
å³ 1 1ã¯ã SH-SY5Y现èã«ãããåçš®éºäŒåå°å
¥ã«ããã¢ãããŒã·ã¹èªå°äœçšã CaSpaSe3/7掻æ§ãŸã㯠LDHãªãªãŒã¹æŽ»æ§ã®æž¬å®ã«ãã解æããçµæã瀺ãã°ã©ã㧠ããã 瞊軞㯠Caspase3/7ã®æŽ»æ§ ïŒäžïŒ ã ãŸãã¯ã³ã³ãããŒã«ã«å¯Ÿããçžå¯Ÿç㪠LDH ã®ãª ãªãŒã¹æŽ»æ§ ïŒäžïŒ ã瀺ãã 暪軞㯠SH- SY5Y现èã«å°å
¥ããéºäŒåã瀺ãã ãã© ãã®å³åŽãã ããã·ãµã€ã¯ãªã³ ïŒDox) ãæ·»å ãããšãããããŠå·ŠåŽãç¡æ·»å ã®å Ž åã®çµæã§ããã
å³ 1 2ã¯ã SH - SY5Y现èã«ãããåçš®éºäŒåå°å
¥ã«ããã¢ãããŒã·ã¹èªå°äœçšã ATPã®å®éãŸãã¯ããã©ãŸãªã¥ã ååç©éå
åå¿ (MTS) ã®æž¬å®ã«ãã解æããçµæ ã瀺ãã°ã©ãã§ããã 瞊軞㯠MTSéå
èœ ïŒäžïŒ ã ãŸã㯠ATPé ïŒäžïŒ ã瀺ãã 暪軞㯠SH - SY5Y现èã«å°å
¥ããéºäŒåã瀺ãã
å³ 1 3ã¯ã SH-SY5Y现èã«ãããåçš®éºäŒåå°å
¥ã«ããã¢ãããŒã·ã¹èªå°äœçšã ãã¹ã㳠· DNAæçè€åäœ ïŒã¢ãã ãªãªãŽãã¯ã¬ãªãœãŒã ïŒ ã®å®éã«ãã解æãã çµæã瀺ãã°ã©ãã§ããã 瞊軞ã¯ã¢ãã ãªãªãŽãã¯ã¬ãªãœãŒã éã瀺ãã 暪軞㯠SH - SY5Y现èã«å°å
¥ããéºäŒåã瀺ãã
å³ 1 4ã¯ã SH - SY5Y现èã«ãããåçš®éºäŒåå°å
¥ã«ããã¢ãããŒã·ã¹èªå°äœçšã Caspase-2, 8, 9掻æ§ã®æž¬å®ã«ãã解æããçµæã瀺ãã°ã©ãã§ããã 瞊軞ã¯ã³ã³ ãããŒã«ã«å¯Ÿããçžå¯Ÿç㪠Caspase- 2, 8ïŒ 9ã®æŽ»æ§ã瀺ãã 暪軞㯠SH- SY5Y现èã«å° å
¥ããéºäŒåã瀺ãã çºæãå®æœããããã®æè¯ã®åœ¢æ
以äžæ¬çºæãå®æœäŸãšããŠæŽã«å
·äœçã«èª¬æããããæ¬çºæã¯è©²å®æœäŸã«éå®ã ããªãããŸãæ¬æ现æžã«ãããŠåŒçšãããå
šãŠã®å
è¡æè¡æç®ã¯ãåç
§ãšããŠæ¬æ 现æžã«çµã¿å
¥ããããã
1 . AF06972éºäŒåã®ã¯ããŒãã³ã°
ããã DNAç 究æããå
¥æãã HJ06972 (KIAA1079)éºäŒåãå¶éé
µçŽ Xholããã³ Notlã§åãåºãã pcDNA3. 1 (Invitrogen) ã® Xhol/Notlãµã€ãã«æ¿å
¥ããã
ããæ Ÿç±æ¥ c DNA (Quick clone cDNA, Clontech) å Ÿãã atgacttcgagacacaggac (é
åçªå·ïŒ 7 ) ãš tcaggtgtgtgagggaaaagct (é
åçªå·ïŒ 8 ) ã®ãã©ã€ããŒãçšã ㊠PCRæ³ã«ãããçŽ 820bPã® AF06972éºäŒåæçãååŸãããåŸããã AF06972éºäŒå æç㯠TA vectorã§ãã pT7-blue2ã«ãµãã¯ããŒãã³ã°ãè¡ã£ãåŸã DNAã·ãŒã¯ã§ã³ ãµãŒã¢ãã« 310 (PE Biosystems) ã«ãã DNAé
åã確èªããã äžèš HJ06972éºäŒåã å°å
¥ãããŠãã pcDNA3. 1ãã¯ã¿ãŒãããå¶éé
µçŽ Xbalããã³ PvulãçšããŠåãåºã ã HJ06972éºäŒåæçãšãå¶éé
µçŽ Pvulããã³ Xholã§åãåºãã AF06972éºäŒåæç ã®äž¡æ¹ã pBluescript IIãã¯ã¿ãŒã® Xbal - Xholãµã€ãã«ãµãã¯ããŒãã³ã°ãã çŽ 4. 8kbã®å
šé· AF06972éºäŒåãååŸããã
2 . MTYKããã³ AF06972éºäŒåã®çµç¹çºçŸååž
Multiple Tissue cDNA Panels (Clontech)ãšå®éå RT- PCRãçšããŠã ããã®çµç¹ ã«ããã AF06972éºäŒåã®çºçŸååžè§£æãè¡ã£ãã å³ã¡ã SYBR Green RT- PCR reagents (PE biosystems)ã®è©Šè¬ãš PRISM 7700 (PE Biosystems)ã®è£
眮ãçšããŠã ã¡äžåäžã®äœ¿çšèª¬ææžã«åŸã€ãŠä»¥äžã®æ¡ä»¶ã«ãŠå®éšãè¡ã€ãã
æ°Ž 18 ÎŒ 1ã Multiple Tissue cDNA Panels 5 ÎŒ 1ã ãã©ã€ããŒïŒ5 ;z M) å 1 1 hAF06972 forwardïŒ atgatgtcacagtctacctgt (é
æ¹å¹¡å·ïŒ 9 )
reverseïŒ cttggagctgagcaggttac (é
å·±åçª"^ïŒ 1 0 )
hAATYK forwardïŒ atcacgcacgtgtctgactc (é
å·±æ¹ Uçª^" : 1 1 )
reverseïŒ agaggcacctgaatctgctg (é
3åçªå·ïŒ äž 2 )
SYBR Green mix 25 /i lã® PCRåå¿æ¶²ã調補ããã PCRã®æ¡ä»¶ã¯ã 94°C㧠30ç§ã 60°C 㧠30ç§ã 72°C㧠30ç§ãšããŠè¡ã£ãã ãã®çµæãè³ã§æã匷ãçºçŸã芳å¯ãããç¶ã ãŠè
èã èŸèã ãªã³ãç¯ã èå
èã§ãçºçŸã芳å¯ãããã MTYKéºäŒåãšåæ§ãª AF06972éºäŒåã®è³ç¹ç°ççºçŸã¯ãè¡æ¶²çŽ°èã«ãããã¢ãããŒã·ã¹ã«é¢äžãã MTYK éºäŒåãšåæ§ãªäœçšã AF06972éºäŒåãè³ã«ãããŠè¡ãã®ã§ã¯ãªãããšãã仮説ã è¯å®ããã
3 · HJ06972éºäŒåãš AF06972éºäŒåã®çºçŸè§£æ
HJ06972éºäŒåãšã ãã® alternative splicing formã§ãã AF06972éºäŒåã®çºçŸ ã®éããæ€åºã§ãããã©ã€ããŒãçšããŠã ã ãè³ã ã ãå¹é€ç¥çµçŽ°è ïŒSH - SY5Y现 èã NT2neuron现èïŒã«ãããçºçŸéã®å·®ãè©äŸ¡ããããã®ãã©ã€ããŒã§ã¯ã HJ06972 éºäŒåã«ã€ããŠã¯çŽ 395bpã AF06972éºäŒåã«ã€ããŠã¯ 315bpã® PCRç£ç©ãåŸãããã HJ06972éºäŒåã¯éåžžã«ããããåçºçŸãèªããããã倧éšå㯠AF06972éºäŒåã§ã ã€ãã åæ§ã«ã MTYKéºäŒåã«ãããŠã HJ06972éºäŒåã«çžåœããéšåã«ããã alternative splicing formãååšãããçºçŸè§£æãè¡ã£ãã MTYKã«ã€ããŠã¯ã ã» ãšãã© alternative splicing formã¯æ€åºãããã 倧éšåã ATTYKéºäŒåã§ãã£ãã (å³ 5 )
æŽã«ã HJ06972ãš AF06972ã«çžåœããããŠã¹ãšã©ããã«ããã alternative splicing formã®æ¢çŽ¢ãè©Šã¿ãã ããªãã¡ã AF06972ã®æ·å
¥å¡©åºé
åãæãã§ãã©ã€ ããŒãèšå®ããæ¿å
¥å¡©åºé
åã®æç¡ã«é¢ããããå¢å¹
ãè¡ããããã«ããã ããã HJ06972ãš AF06972ãšã«çžåœãã alternative splicingïŒormãååšããã°ã 倧ãã ã®ç°ãªã 2ã€ã®å¢å¹
ç£ç©ã確èªã§ããã¯ãã§ããã PCRã«çšãããã©ã€ããŒã®å¡©åº é
åã以äžã«ç€ºãã
ããã forward :aagccttctgggttccaag (é
å·±åçª ïŒ 1 3 )
reverseïŒ agttctccatcactcctgag (é
å·±åçªå·ïŒ 1
ããŠã¹ forward: aagccttctgggttccaag (ç® Gåçªå·ïŒ 1 3
reverseïŒ cgctttccatcactcctgag (gGåçªå·ïŒ 1 5
ãã®çµæã ããŠã¹ãšã©ããã«ãããŠã¯ã AF06972ã«çžåœãããã³ãã®ã¿ã芳å¯ã ããã ã©ãããšããŠã¹ã«ãããŠã¯ã HJ06972ã«çžåœãã alternative splicing form ã¯ç¢ºèªã§ããªãã£ãã ãããã£ãŠã æ¬çºæã«ãããŠèŠåºãããæ°èŠãª alternative splicing formã§ãã AF06972ã¯ã ããã®ã¿ãªããã ããŠã¹ãšã©ããã«ãããŠãäž»èŠ ãªçºçŸç£ç©ã§ãããšèããããã
4 . PC12现èã«ãããéºäŒåå°å
¥ã«ããç¥çµçªèµ·äŒžå±äœçš
PC12ã« EGFP (enhanced GFP, Clontech) ãšç®çã®éºäŒåããšã¬ã¯ããã¬ãŒã·ãšã³
æ³ãçšããŠä»¥äžã®æ¡ä»¶ã«ãŠå°å
¥ããã
5 X 106现è/ mlå¹å° ïŒRPIM 1640+ 10% HS+ 5% FBS) 250 1
EGFPãã©ã¹ãã 4 g
ç®çéºäŒå 8 z g
250Vã 950
Collagen type IVã³ãŒãã£ã³ã°ãæœããã¥ãšã«ã§ 18ã24æéå¹é€ããåŸã å¹å°ã 亀æããã ããã« 48æéå¹é€ããåŸã G-418ãæ·»å ããã 4æ¥éå¹é€åŸãé¡åŸ®é¡äžã§ 芳å¯ãè¡ã£ãã
å®éšã¯ 3åç¹°ãè¿ãã çµæ㯠EGFPãéºäŒåå°å
¥ã®ã³ã³ãããŒã«ãšãã 4ã7èŠéã 31ãïŒ 150ã® EGFP positive现èã«ã€ããŠãç¥çµçªèµ·ã®äŒžå±ãèŠããããã®ã®å²åãç® åºããã çµæã¯æ¬¡ã®åŒã«ãã£ãŠç®åºããç¥çµçŽ°èã®äŒžå±ç (ïŒ
of neurite outgrowth)ã§è¡šããã ãŸãã äœæ¿åºŠ ïŒlng/ml) ã® NGFã®ç¥çµçªèµ·äŒžå±äœçšã«å¯Ÿãã åéºäŒåã®åœ±é¿ã«ã€ããŠãåæ§ã«è©äŸ¡ããã
ç¥çµçŽ°èã®äŒžå±ç = (䌞å±ãèŠããã现èæ° Zç·çŽ°èæ°ïŒ X 1 0 0
HuCã PKAã hAATKY (HJ03494) ã HJ06972ã®ãããããã³ã³ãããŒã«ã«æ¯ã¹ãŠã éº äŒåãéå°çºçŸãããå Žåã«ãããŠãç¥çµçªèµ·ã®äŒžå±äœçšã瀺ãããšã確èªãããã HJ06972ã§ã¯ãç¥çµçªèµ·ã®äŒžå±äœçšãåŸæ¥å ±åãããŠãã HuCãããããã«åŒ·ãäœçš ã芳å¯ããã ïŒå³ 6 ) ã äœæ¿åºŠã® NGFã«ããç¥çµçªèµ·äŒžå±äœçšã«å¯ŸããŠãä»ã«æ¯ã¹ ãŠæã匷ãä¿é²äœçšã確èªããã ïŒå³ 7 ) ã
5 . HJ06972ã® CREB転å掻æ§ã®æž¬å®
äžèšã® PC12ãçšããç¥çµçªèµ·äŒžå±äœçšã®æ€èšã«ããã HJ06972ãéå°çºçŸã«ãã ç¥çµçªèµ·äŒžå±äœçšãæããããšãæããã«ãªã£ãã PC12现èã«ãããç¥çµçªèµ·ã®äŒž å±ã«ã¯å€ãã®å Žåã CREB転å掻æ§ãé¢äžããŠããã®ã§ HJ06972ã® CREB転å掻æ§ã«ã€ ããŠæ€èšããã
ãŸãã PC12ãåã¥ãšã«ã« 1 X 106现èæãã ãŒæ 37°Cã§ã€ã³ãã¥ããŒã·ã§ã³ããã PC12现èãž CRE-ã«ã·ãã§ã©ãŒãŒ ã¬ããŒã¿ãŒéºäŒå pCRE- Luc (Stratagene) ã ãã
ãŽç®çéºäŒå (HJ06972) çºçŸãã¯ã¿ãŒããªãããšã¯ãã¡ãã³æ³ã§å°å
¥ããã CRE - ã«ã·ãã§ã©äžãŒã¬ããŒã¿ãŒéºäŒåã 2. 0 gã ããã³ç®çéºäŒå (HJ06972)çºçŸã¹ ã¯ã¿äž 1. 0 gã现èäžæž
ïŒRPMI1640+20%ã¥ãè¡æž
+ 10%ã¥ã·è¡æž
ïŒ ã«å BãããŒæ ã€ã³ãã¥ããŒã·ã§ã³ããŠçŽ°èå
ã«ãã¯ã¿äžãå°å
¥ããã åŸããã圢質転æ现èãã 1æ¥å¹é€ããåŸã« lng/mlã® NGFãæ·»å ãã 6æéåŸã« CREBã®è»¢å掻æ§ãã«ã·ãã§ã© âãŒã«ããã¬ããŒã¿ãŒéºäŒååæã«ããæ€èšããã
ãã®çµæã HJ06972éºäŒåã®å°å
¥ã«ããã CREBã®è»¢åããããã«æŽ»æ§åãããåŸ åã芳å¯ãããã åæ§ã« MTYKã§ãéåžžã«ãããã« CREB転å掻æ§ãäžæããããšã æããã«ãªã£ã ïŒå³ 8 ) ã ãã®ããšã«ããã HJ06972ã®ç¥çµçªèµ·äŒžå±äœçšã«ã¯ã ã ã® CREB転å掻æ§ä¿é²ãé¢äžããŠããå¯èœæ§ãèããããã
6 . Jurkat现èã«ãããéºäŒåå°å
¥ã«ããã¢ãããŒã·ã¹èªå°äœçš
HJ06972ã®ã¢ãããŒã·ã¹èªå°æŽ»æ§ã調ã¹ãããã«ã Jurkat现èã« HJ06972éºäŒå㟠ãã¯æ¢ç¥ã®ã¢ãããŒã·ã¹é¢é£éºäŒåãå°å
¥ããã¢ãããŒã·ã¹ãèµ·ããã现èã®æ°ã 調ã¹ãã
ãŸãã ã³ã³ãã«ã§ã³ãã«ãªããŸã§å¹é€ãã 2mlã® Jurkat现èãã 18mlã®æ°ããå¹ å°ã«å ããããšã«ããã现èãå¹é€ããã å¹å°ã«ã¯ 10% ã¥ã·èä»è¡æž
(FBS) å«æ RPMI 1640ãçšããã
次ã«ããšã¬ã¯ãããã¬ãŒã·ã§ã³æ³ãçšããŠã Jurkat现èã«ç®çéºäŒåãå°å
¥ããã å
·äœçã«ã¯ã 现èãé å¿ããŠååããåŸã å¹å°ã«åæžæ¿ãã 5X 106现è/ mlã®çŽ°è æžæ¿æ¶²ã調補ããã ç®çéºäŒåã®çµã¿èŸŒãŸãããã©ã¹ãããã ãã©ã¹ãã DNAã®æ çµæ¿åºŠã 10 g/250^ 1ã«ãªãããã«çŽ°èæžæ¿æ¶²ã«å ããæ°·äžã§ 10åéé眮ããã ã ã®æº¶æ¶² 250ÎŒ 1ããšã¬ã¯ãããã¬ãŒã·ãšã³çšãã¥ã¹ããã«ç§»ãã Genepulserll
(Bio-Rad) 㧠250Vã 950 Fã®ãã«ã¹ãäžããããšã«ããã éºäŒåãå°å
¥ããã æ°· äžã§ 10åéé眮ããåŸã 4mlã® M thapsigarginæ·»å ããŸãã¯äžæ·»å å¹å°ãçšããŠã 24æéå¹é€ããã
现èããã¥ãŒãã«ååãã é å¿ã«ããäžæž
ãé€ããã åãã¥ãŒãã« 2 w M
Rhodamine 123ãå ãã 37ã (ïŒã 5% C02äžã«ãŠ 20åéã€ã³ãã¥ããŒãããã é å¿ã«ã ãäžæž
ãé€ããåŸã PI液ãå ããŠã¢ãããŒã·ã¹ãèµ·ããã现èã FACSã§è§£æããã
Bad, Caspase3ã HJ06972ã®éºäŒåãéå°çºçŸãããå Žåã«ã¯ãã¢ãããŒã·ã¹èªå° 掻æ§ãèŠãããã ãããšã¯éã«ã Bcl2ã®éºäŒåãéå°çºçŸããã ^^ã«ã¯ã ã¢ãã äžã·ã¹æå¶æŽ»æ§ãèŠããã ïŒå³ 9 )ã ããã«ã 1 /x Mã® thapsigarginãæ·»å ããå Žå ã«ã¯ã thapsigarginãæ·»å ããªãã£ãå Žåãšåæ§ã®åŸåãèŠãããã ãã ããç¹ã« HJ06972éºäŒåãéå°çºçŸãããå Žåã«ã€ããŠã¯ã thapsigarginã®ã¢ãããŒã·ã¹èª å°æŽ»æ§ãä¿é²ããåŸåãèŠããã ïŒå³ 9 )ã
thapsigarginãæ·»å ãããšçŽ°è質å
ã® Ca2+æ¿åºŠãäžæãã CREBããªã³é
žåãåã ãŠæŽ»æ§ã£ããããšèããããããšããã HJ06972ã®ã¢ãããŒã·ã¹èªå°äœçšã«ãã CREB 転å掻æ§ä¿é²ãé¢äžããŠããå¯èœæ§ã瀺åãããã
7 . ã¢ãããŒã·ã¹ã®èªå°ã«äŒŽã MTYKãš mAF06972ã®çºçŸã¬ãã«ã®å€å
1 X106åã®ãã¥ã¹ B现èç³»å¹é€çŽ°èã§ãã Ba/F3现èïŒRCB0805, RIKEN Cell Bank) ã 10% FCSãš 5 ng/mlã®ããŠã¹ã€ã³ã¿ãŒãã€ãã³äž 3 (IL - 3)ãå«ã RPMIå¹å°ã§ 3 7 °Cã 5 % C02ã®æ¡ä»¶ã§å¹é€ããã现èã PBS㧠3åæŽæµããåŸã IL- 3ãé€ãã 10% FCSãå«ã RPMIå¹å°ã«äº€æã㊠5 % C02ã®æ¡ä»¶ã§å¹é€ãã¢ãããŒã·ã¹ã®èªå°ãè¡ã€ ãã IL- 3ãé€å»åŸã 0ã 4ã 8ã 1 2ã 2 4ãããã³ 4 8æéåŸã®çŽ°èãååããŠã RT - PCRã«ãã€ãŠ MTYKãš AF06972éºäŒåã®çºçŸè§£æãè¡ã€ãã P C Rã«çšãã primer ã®å¡©åºé
åã¯ãããã以äžã®ãšããã§ããã
AATYK ïŒ forwardïŒ aatcactccctacgttcctgg (é
å·±åçªå·ïŒ 1 6 )
reverseïŒ tctcaagcctctgtgtatc (ç® då Ÿ·å·ïŒ 1 7ã
mAF06972ïŒ forwardïŒ agtacctgttgtagaagttc (é
å·±åçªå·ïŒ 1 8 )
reverseïŒ ctggaactgggatggagctg (é
å·±åçªå·ïŒ 1 9 )
HPRT ïŒ forward : gcatacctaatcattatgctg (é
åçªå·ïŒ 2 0 )
reverseïŒ gtctggaatttcaaatccaac (é
å·±å Ÿå·ïŒ 2 1 )
PCRã®æ¡ä»¶ã¯ã MTYKãš AF06972éºäŒåã«ã€ããŠã¯ã 9 4 °C 3 0ç§ã 6 0 °C 3 0ç§ã
7 2 °C 3 0ç§ã§ 3 0ãµã€ã¯ã«ã®åå¿ãè¡ã£ãã HPRTã«ã€ããŠã¯ãåæ¡ä»¶ã§ 2 5ãµã€ ã¯ã«ã®åå¿ãè¡ã£ãã åå¿æ¶²ã¯ 2 %ã¡ã¬ããŒã¹ã²ã«ãçšããé»æ°æ³³åãè¡ã£ãåŸã ã§ããžã¥ã ãããã€ã (EtBr)ã§æè²ããã çµæãå³ 1 0ã«ç€ºããã
ãã®çµæã MTYKãš AF06972éºäŒå㯠IL- 3é€å»ã«ãã Ba/F3现èã®ã¢ãããŒã·ã¹ ã®èªå°ã«ãšããªãã çµæçã«çºçŸéã®å¢å ã芳å¯ãããã
8 . AF06972éºäŒåã®ã¯ããŒ-ã³ã°
ããè³ç±æ¥ cDNA(Quick clone cDNA, Clontech)ããã次ã®å¡©åºé
åãæãããã© ã€ãäžãçšã㊠PCRæ³ã«ãã AF06972éºäŒåæçãååŸããã
ctactggactctttaggatc (é
æ¹! |çªå·ïŒ 2 2 )
agagcggccgctcaggtgtgtgagggaaaagct æ¹ [jçªå· : 2 3 )
åŸããã AF06972éºäŒåæçã¯å¶ é
µçŽ Spelãã㎠Notlã§æ¶åããããã DNAç 究 æããå
¥æãã HJ06972 (KIM1079) in pBS (pBluescript II SK(+) ) (éºäŒå㯠Sal I - Notl siteã«æ¿å
¥ïŒ ãå¶éé
µçŽ Spelããã³ Notlã§åãåºããæ®ãã®ãã®ãžæ¿å
¥ã ããæ¿å
¥éšå㯠DNAã·ãŒã¯ã§ã³ãµäžã¢ãã« 310 (PE Biosystems)ã«ãã DNAé
åãç¢ºèª ããã AF06972 in pBSãšããã
9 . Flag- HJ06972ããã㯠Flag- AF06972ã®äœè£œ
次ã®å¡©åºé
åãæãããã©ã€ããŒãçšã㊠PCRæ³ã«ãã Xhol- FLAG- HJ06972 - Sail æçãååŸããã
agactcgaggccaccatggattacaaggatgacgacgataagatgccggggccgccggcgtt (6972 Xhol Fl :XhoI- FLAG- atg) (é
åçªå·ïŒ 2 4 )
gctgtttgtgttcggcttcaga (6972 Sail R) (é
åçªå·ïŒ 2 5 )
åŸãããæçã Xholããã³ Sailã§å¶éé
µçŽ æ¶åãã HJ06972 in pBSããã³ AF069 72 in pBSãå¶éé
µçŽ Xholããã³ Sailã§åãåºããæ®ãã®ãã®ãžæ¿å
¥ããã
1 0 . çµæãã¢ãããŠã£ã«ã¹ DNAã®äœè£œ
Flag- HJ06972 in pBSããã㯠Flag - AF06972 in pBSãå¶éé
µçŽ Xholã§åŠçãã åŸã«ã T4 DNA polymerase㧠bluntã£åãã ããã« Notlã§åŠçããã pTRE - 3 1:1:16ã¯
balã§åŠçããåŸã«ã T4 DNA polymerase㧠bluntã£åãã ããã« Notlã§åŠçããã W unt-Notl siteã«åéºäŒåã®äžèš blunt- Notlæçãæ·å
¥ããã pTRE- 31111 16ãã å
« deno-X DNAã®çµæã㯠Adeno- X⢠Tet-0ffM Expression System (Clontech) ã®æ·» ä»ããã¥ã¢ã«ã«åŸã£ãã
1 1 . Caspase-3/7, LDH
ããã¥ãŠãŒããã©ã¹ããŒã311-3Â¥5¥现èã961611 plateã« 1 wellããã 2. 5 x 104 åæãã 37°CïŒ 5% C02æ¡ä»¶äžã§ãŒæå¹é€ããã 现èããã¬ãŒãäžã«ããã¯ãã€ã㊠ããããšã確èªåŸã å¹é€ãã¬ãŒãããå¹å°ãé€å»ããŠã å¹å°ã§ 3. 2åç³»ååžéãã çµæãã¢ãããŠã€ã«ã¹æ¶² 30 ÎŒÎãæ·»å ãã 37°CïŒ 5% C02æ¡ä»¶äžã§çŽ 2æéå¹é€ãã æ æãããã çµæããŠã£ã«ã¹ã¯ããã©ãµã€ã¿ãªã³ã«ãã£ãŠéºäŒåçºçŸã調ç¯ãã Adeno-X⢠Tet-Off⢠Expression System (ã¯ãã³ããã¯ç€ŸïŒ ãå©çšãã 調ç¯ãŠã£ã« ã¹ ïŒTet- Off) ãšå¿çæ§ã®åéºäŒåçµæããŠã£ã«ã¹ãçšããã ãã®åŸã æ·»å ãã㥠ã£ã«ã¹æ¶²ãé€å»ãã ããã©ãµã€ã¯ãªã³ãå«ãŸãªãè¡æž
ã 1%å«ãæ°ããå¹å° 100 ΌΠãæ·»å ãã 37°CïŒ 5% C02æ¡ä»¶äžã§å¹é€ããã ãã®ãšã察ç
§ãšããŠã éºäŒåçºçŸãæ å¶ããããã·ãµã€ã¯ãªã³ ïŒããã©ãµã€ã¯ãªã³èªå°äœïŒ 1 ÎŒÎãå«ãå¹å°ãå ããã¥ã§ ã«ãçšæããã 48æéåŸã现èå
ã® Caspase- 3/7ã®æŽ»æ§ãšçŽ°èæ»ã«äŒŽã£ãŠéé¢ãã ã LDHã®æŽ»æ§ã枬å®ããããšã«ããã éºäŒåã®éå°çºçŸã«ãã现èæ»èªå°ã«ã€ã㊠ïŒå¹³æ€ãã«ã Caspase- 3ïŒ 7掻æ§ã¯ã Apo-0ne⢠homogeneous Caspase-3/7 assay ã,å£ ã¡ã¬ïŒã«ãã£ãŠè©äŸ¡ããããŸã LDH掻' 14ã¯ãå¹é€äžæž
ããµã³ãã«ãšã㊠Cytotoxicity Detection Kit (LDH) (ããã·ã¥ïŒ ãçšããŠè©äŸ¡ããã ãããã®è©äŸ¡æ¹æ³ãã æ·»ä» ææžã«åŸã£ãã
ãã®çµæã AF06972ããã³ HJ06972éºäŒåãå°å
¥ããåŸãããã©ãµã€ã¯ãªã³ãé€ã ãŠå°å
¥éºäŒåã®çºçŸãèªå°ãã SH- SY5Y现èã§ã¯ã lacZéºäŒåãå°å
¥ãã现èã«å¯Ÿ ããŠãŠã€ã«ã¹ã®åžéç³»åã«ããéºäŒåã®çºçŸéã«æ¯äŸãã匷ã LDHã®ãªãªãŒã¹æŽ»æ§. ã¢ãããŒã·ã¹å®è¡ãããã¢ãŒãŒã§ãã Caspase3/7ã®åŒ·ã掻æ§åãèªããããïŒå³ 1 1 )ãäžæ¹ã ããã·ãµã€ã¯ãªã³ãæ·»å ããŠéºäŒåçºçŸãæå¶ãã SH- SY5Y现èã§ã¯ã
LDHã®ãªãªäžã¹æŽ»æ§ã CasPase3/7掻æ§ãšãã« lacZéºäŒåãå°å
¥ããå ŽåãšåçšåºŠã§ ãããã¢ãããŒã·ã¹èªå°ã¯èªããããªãã£ãïŒå³ 1 1 )ã以äžã®ããšããã AF06972 ããã³ HJ06972éºäŒåãéå°çºçŸãããããšã«ããã SH - SY5Y现èã® Caspase - 3ãã ㎠7ã®æŽ»æ§åã䌎ã现èæ»ãèªå°ããããšãæãããšãªã£ãã
1 2 . ATP, MTS
ããã¥ãŠãŒããã©ã¹ããŒã311-3Â¥5¥现èã961611 plateã« 1 wellããã 2. 5 x 104 åæãã 37°C, 5% C02æ¡ä»¶äžã§ãŒæå¹é€ããã 现èããã¬ãŒãäžã«ããã¯ãã€ã㊠ããããšã確èªåŸãå¹é€ãã¬ãŒãããå¹å°ãé€å»ããŠãå¹å°ã§åžéããçµæãã¢ã ããŠã£ã«ã¹æ¶² 30 ÎŒÎãæ·»å ãã 37°CïŒ 5% C02æ¡ä»¶äžã§çŽ 2æéå¹é€ãã ææãããã çµæããŠã£ã«ã¹ã¯ããã©ãµã€ã¯ãªã³ã«ãã£ãŠéºäŒåçºçŸã調ç¯ãã Adeno- X⢠Tet- Off⢠Expression System (ã¯ãã³ããã¯ç€ŸïŒãå©çšãã調ç¯ãŠã£ã«ã¹ïŒTet- Off) ãšå¿çæ§ã®åéºäŒåçµæããŠã£ã«ã¹ãçšããããã®åŸãæ·»å ãããŠã£ã«ã¹æ¶²ãé€å» ããããã©ãµã€ã¿ãªã³ãå«ãŸãªãè¡æž
ã 1%å«ãæ°ããå¹å° ÎÎÎ ÎŒÎãæ·»å ãã 37°CïŒ 5% C02æ¡ä»¶äžã§å¹é€ããã ãã®ãšã察ç
§ãšããŠã éºäŒåçºçŸãæå¶ããããã·ãµã€ã¯ ãªã³ ïŒããã©ãµã€ã¯ãªã³èªå°äœïŒ 1 ÎŒÎãå«ãå¹å°ãå ããã¥ãšã«ãçšæããã 48 æéåŸã 代è¬æŽ»æ§ã®ãã现èã«ç±æ¥ãã Î΀Ρã®å®éãããã¯ããã©ãŸãªã¥ã ååç© éå
åå¿ (MTS) ã枬å®ããããšã«ããã éºäŒåã®éå°çºçŸã«ãã现èæ»èªå°ã«ã€ ããŠè©äŸ¡ããã Î΀Ρã¯ã CellTiter-Glo⢠Luminescent Cell Viability Assay (ãã ã¡ã¬ïŒã«ããå®éããã MTSã¯ã CellTiter 96β AQueous One Solution Cell Proliferation Assay (ããã¡ã¬ïŒ ãçšããŠå®éããã ãããã®å®éæ¹æ³ãã æ·»ä» ææžã«åŸã£ãã
ãã®çµæã AF06972éºäŒåãå°å
¥ããåŸã ããã©ãµã€ã¯ãªã³ãé€ããŠå°å
¥éºäŒå ã®çºçŸãèªå°ãã SH-SY5Y现èã§ã¯ã ããã·ãµã€ã¯ãªã³ãæ·»å ããŠéºäŒåçºçŸãæ å¶ãã现èã«æ¯èŒã㊠ATPéã MTSéå
èœãšãã«æžå°ããŠããã代è¬æŽ»æ§ã®æžå°ãèª ãããã ïŒå³ 1 2 ) ã ãªãã ããã·ãµã€ã¯ãªã³ãæ·»å ããŠéºäŒåçºçŸãæå¶ãã现 èã®ä»£è¬æŽ»æ§ã¯ãŠã€ã«ã¹ã«ããéºäŒåã®å°å
¥ãè¡ã£ãŠããªã现è controlãšåçšåºŠ
ã§ãã£ã ïŒå³ 1 2 ) ã 以äžã®ããšããã AF06972éºäŒåãéå°çºçŸãããããšã«ã ãã SH-SY5Y现èã®ä»£è¬æŽ»æ§ãæžå°ããŠããã 现èæ»ãèªå°ããããšãæãããšãª ã€ãã
1 3 . DNA fragmentation
ããããŠãŒããã©ã¹ããŒã SH-SY5Y现èã 96- well plateã« 1 wellããã 2. 5 x 104 åæãã 37°CïŒ 5% C02æ¡ä»¶äžã§äžæ©å¹é€ããã 现èããã¬ãŒãäžã«ããã¯ãã€ã㊠ããããšã確èªåŸãå¹é€ãã¬ãŒãããå¹å°ãé€å»ããŠãå¹å°ã§åžéããçµæãã¢ã ããŠã£ã«ã¹æ¶² 30 ÎŒÎãæ·»å ãã 37°C, 5% C02æ¡ä»¶äžã§çŽ 2æéå¹é€ãã ææãããã çµæããŠã€ã«ã¹ã¯ããã©ãµã€ã¯ãªã³ã«ãã€ãŠéºäŒåçºçŸã調ç¯ãã Adeno-X⢠Tet-Off⢠Expression System (ã¯å£ã³ããã¯ç€ŸïŒãå©çšãã調ç¯ã¥ã£ã«ã¹ ïŒTet-Off) ãšå¿çæ§ã®åéºäŒåçµæããŠã£ã«ã¹ãçšããããã®åŸãæ·»å ãããŠã£ã«ã¹æ¶²ãé€å» ããããã©ãµã€ã¯ãªã³ãå«ãŸãªãè¡æž
ã 1%å«ãæ°ããå¹å° 100 ÎŒÎãæ·»å ãã 37°C, 5% C02æ¡ä»¶äžã§å¹é€ããã ãã®ãšã察ç
§ãšããŠã éºäŒåçºçŸãæå¶ããããã·ãµã€ã¯ ãªã³ ïŒããã©ãµã€ã¯ãªã³èªå°äœïŒ 1 ÎŒÎãå«ãå¹å°ãå ããã¥ãšãã¬ãçšæããã 48 æéåŸã 现èãã¢ãããŒã·ã¹ã«é¥ã£ãåŸã«çŽ°è質ã«åºçŸãããã¹ ãã³ ' DNAæçè€ åäœ ïŒã¢ãã æãªãŽãã¯ã¬ãªãœãŒã ) ãå®éããããšã«ãããéºäŒåã®éå°çºçŸã« ãã现èæ»èªå°ã«ã€ããŠè©äŸ¡ãããã¢ããã¯ã¬ãªãœãŒã ãããã³ãªãªãŽãã¯ã¬ãªãœ ãŒã ã¯ã Cell Death Detection ELISA PLUS (ããã·ã¥ïŒ ãçšããŠå®éããã å®é æ¹æ³ã¯ã æ·»ä»ææžã«åŸã£ãã ãªãã ãµã³ãã«ã¯çŽ°è溶解液 5 Lã« Lysis buffer 1 5 Lãæ·»ã«å©ããŠèª¿è£œããã
ãã®çµæã AF06972ããã³ HJ06972éºäŒåãå°å
¥ããåŸãããã©ãµã€ã¯ãªã³ãé€ã ãŠå°å
¥éºäŒåã®çºçŸãèªå°ãã SH- SY5Y现èã§ã¯ã lacZéºäŒåãå°å
¥ãã现èã«æ¯ èŒããŠã¢ãã ãªãªãŽãã¯ã¬ãªãœãŒã ã®é¡èãªå¢å ãèªãããã ïŒå³ 1 3 ) ã äžæ¹ã ããã·ãµã€ã¯ãªã³ãæ·»å ããŠéºäŒåçºçŸãæå¶ãã SH-SY5Y现èã§ã¯ã lacZéºäŒå ãå°å
¥ããå ŽåãšåçšåºŠã§ãããã¢ãããŒã·ã¹èªå°ã¯èªããããªãã£ãïŒå³ 1 3 )ã 以äžã®ããšããã AF06972ããã³ HJ06972éºäŒåãéå°çºçŸãããããšã«ããã
SH - SY5Y现èã® DNAæçåã䌎ã现èæ»ãèªå°ããããšãæãããšãªã£ãã
1 4 . Caspase-2, 8, 9
ããããŠãŒããã©ã¹ããŒã SH - SY5Y现èã 96iell plateã« 1 wellããã 2. 5 x 104 åæãã 37°C, 5% C02æ¡ä»¶äžã§äžæ©å¹é€ããã 现èããã¬ãŒãäžã«ããã¯ãã€ã㊠ããããšã確èªåŸãå¹é€ãã¬ãŒãããå¹å°ãé€å»ããŠãå¹å°ã§åžéããçµæãã¢ã ããŠã£ã«ã¹æ¶² 30 ÎŒÎãæ·»å ãã 37ãC, 5% C02æ¡ä»¶äžã§çŽ 2æéå¹é€ãã ææãããã çµæããŠã£ã«ã¹ã¯ããã©ãµã€ã¯ãªã³ã«ãã€ãŠéºäŒåçºçŸã調ç¯ãã Adeno - X⢠Tet-0f f⢠Expression System (ã¯ãã³ããã¯ç€ŸïŒãå©çšãã調ç¯ãŠã£ã«ã¹ïŒTet- Off) ãšå¿çæ§ã®åéºäŒåçµæããŠã£ã«ã¹ãçšããããã®åŸãæ·»å ãããŠã£ã«ã¹æ¶²ãé€å» ããããã©ãµã€ã¿ãªã³ãå«ãŸãªãè¡æž
ã 1%å«ãæ°ããå¹å° 100 ÎŒÎãæ·»å ãã 37°C, 5% C02æ¡ä»¶äžã§å¹é€ããã ãã®ãšã察ç
§ãšããŠã éºäŒåçºçŸãæå¶ããããã·ãµã€ã¯ ãªã³ ïŒããã©ãµã€ã¯ãªã³èªå°äœïŒ 1 ÎŒÎãå«ãå¹å°ãå ããã¥ãšã«ãçšæããã 24 æéåŸã现èå
ã® Caspase - 2ïŒ 8ïŒ 9ã®å掻æ§ãè©äŸ¡ãããæ¹æ³ã¯ Caspase- 2 Assay Kit, Fluorometric (å,ã¬ããªã±ã ã Caspase-8 Activity Assay Fluorometric (ãªã³ã³ ãžãŒã³) ã Caspase- 9 Activity Assay Fluorometric (ãªã³ã³ã³ãŒã³) ãçšã¬ãœãŠã æ·»ä»ææžã«åŸã£ãŠè¡ã£ãã
ãã®çµæã AF06972éºäŒåãå°å
¥ããåŸã ããã©ãµã€ã¯ãªã³ãé€ããŠå°å
¥éºäŒå ã®çºçŸãèªå°ãã SH- SY5Y现èã§ã¯ã ããã·ãµã€ã¯ãªã³ãæ·»å ããŠéºäŒåçºçŸãæ å¶ãã现èã«æ¯èŒã㊠Caspase- 2ïŒ 8ïŒ 9ã®æŽ»æ§åãèªãããã ïŒå³ 1 4 ) ã ãªãã ããã·ãµã€ã¯ãªã³ãæ·»å ããŠéºäŒåçºçŸãæå¶ãã现èã®å掻æ§ã¯ãŠã£ã«ã¹ã«ã ãéºäŒåã®å°å
¥ãè¡ã£ãŠããªã现è controlãšåçšåºŠã§ãã£ã ïŒå³ 1 4 ) ã 以äžã® çµæããã AF06972éºäŒåãéå°çºçŸãããããšã«ããã¢ãããŒã·ã¹èªå°ããã㢠ãŒãŒã§ãã Caspase- 2ïŒ 8ïŒ 9ã掻æ§ã£åãã ã¢ãããŒã·ã¹ã·ã°ãã«ã掻æ§ã£åãããã ãšãæãããšãªã£ãã ç£æ¥äžã®å©çšã®å¯èœæ§
æ¬åªæã«ããã æ°èŠãªéºäŒå AF06972ãæäŸãããã ãã®éºäŒåã¯ã ã¢ãããŒã· ã¹ãèªå°ãã掻æ§ã䞊ã³ã«ç¥çµçŽ°èã®ååãããã¯å¢æ®ãèªå°ãã掻æ§ãæããè çœè³ªãã³ãŒãããŠãããæŽã«æ¬çºæã¯ããã®æ§é ã¯æ¢ç¥ã§ãããæ©èœã¯è§£æãã㊠ã㪠ãHJ06972éºäŒåãã AF06972éºäŒåã«ãã£ãŠã³ãŒããããèçœè³ªãšåã掻æ§ã æããèçœè³ªãã³ãŒãããŠããããšãæããã«ããã
æ¬çºæã«ãã£ãŠèŠåºãããããããã®èçœè³ªã®ç¥çµçŽ°èã®ååèªå°æŽ»'æ§ã¯åŒ·å㧠ããã ãããã£ãŠã ãã®èçœè³ªã¯ãç¥çµçŽ°èã®ååãå¢æ®ã«ãããŠéèŠãªåœ¹å²ãæ ãããšæãããããã®ããã ãã®èçœè³ªãã®ãã®ã ãããã¯ãã®èçœè³ªãã³ãŒãã ãéºäŒåã¯ãç¥çµçŽ°èã®ååãå¢æ®ããããã¯çŽ°èæ»ãé¢é£ããå€ãã®çŸæ£ã®èšºæ ææšãšããŠéèŠã§ããã ãããèçœè³ªãéºäŒåã®æž¬å®æ¹æ³ãšããã®æž¬å®æ¹æ³ã«åºã¥ ã蚺ææ¹æ³ãå®çŸããæ¬çºæã®æ矩ã¯å€§ããã
ãããã¯ãã®èçœè³ªãã®ãã®ããããã¯ãã®èçœè³ªã®æŽ»æ§ãçºçŸã調ç¯ããããš ãã§ããååç©ã¯ãç¥çµçŽ°èã®çŽ°èæ»ãåã£ããããã¯å¢æ®ãé¢äžããçŸæ£ã«ãããŠã æçšãªæ²»çå€ãšãªãã
ãããã®éºäŒåã«ãã£ãŠã³ãŒããããèçœè³ªã¯ã现èæ»ããããã¯ç¥çµçŽ°èã®å åãå¢æ®ã«ãã£ãŠç¹åŸŽä»ããããçŸæ£ã®æ²»çã«æçšã§ããã ããå
·äœçã«ã¯ã ãã ãã®ããªãã¯ã¬ãªããããããã¯ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªã¯ã æ£åžžãªå¶åŸ¡ã倱ã€ã现èã«çŽ°èæ»ãããããããšã«ãã€ãŠæ²»çå¹æãéæããã ãšãã§ããã ãããã¯ãç¥çµçŽ°èã®ååãå¢æ®ãéããŠãæ²»çå¹æãéæããããš ãã§ããã
æŽã«æ¬çºæã¯ã ãããã®ããªãã¯ã¬ãªããã®ã¢ã³ãã»ã³ã¹ããããã¯ãããã®ã ãªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªã«å¯Ÿãããããã³ããã¬ãã£ãã®åœ¢ 質ãæããèçœè³ªãã现èæ»ããããã¯ç¥çµçŽ°èã®ååãå¢æ®ã«ãã£ãŠç¹åŸŽä»ãã ããçŸæ£ã®æ²»çã«æçšã§ããã ããå
·äœçã«ã¯ã ãããã®ããªãã¯ã¬ãªããã ãã ãã¯ããªãã¯ã¬ãªããã«ãã£ãŠã³ãŒããããèçœè³ªã¯ãçŸç
ã®åå ãšãªã£ãŠããç° åžžãªçŽ°èæ»ãæå¶ããããšã«ãã£ãŠæ²»çå¹æãéæããããšãã§ããã ãããã¯ã
çŸæ£ã®åå ãšãªã£ãŠããç¥çµçŽ°èã®ç°åžžãªåã£ããå¢æ®ãæå¶ããããšã«ãããæ²»ç å¹æãéæããããšãã§ããã .
ãããã¯æ¬çºæã¯ã AF06972éºäŒåã HJ06972éºäŒåã ãããã¯ãããã®éºäŒåãš æ©èœçã«åçãªéºäŒåãå©çšãããã¢ãããŒã·ã¹ãèªå°ãã掻æ§ã䞊ã³ã«ç¥çµçŽ°è ã®åã£åãããã¯å¢æ®ãèªå°ãã掻æ§ã調ç¯ãã掻æ§ãæ€åºããæ¹æ³ãæäŸãããå ããŠæ¬çºæã¯ã ãã®æ¹æ³ãå¿çšããã ã¢ãããŒã·ã¹ãèªå°ãã掻æ§ã䞊ã³ã«ç¥çµçŽ° èã®ååãããã¯å¢æ®ãèªå°ãã掻æ§ã調ç¯ãã掻æ§ãæããåè£ç©è³ªã®è©äŸ¡æ¹ æ³ãæäŸããã
æ¬çºæã®è©äŸ¡æ¹æ³ã«ãã£ãŠåŸãããšãã§ããååç©ãã现èæ»ããããã¯ç¥çµçŽ° èã®åã£ããå¢æ®ã«ãã£ãŠç¹åŸŽä»ããããçŸæ£ã®æ²»çã«æçšã§ãããããšãã°æ¬çºæ ã«ãã£ãŠåŸãããšãã§ãããã¢ãããŒã·ã¹ãèªå°ãã掻æ§ã䞊ã³ã«ç¥çµçŽ°èã®åã£å ãããã¯å¢æ®ãèªå°ãã掻æ§ãæå¶ïŒdown regulation)ããååç©ã¯ã çŸç
ã®åå ãšãªã£ãŠããç°åžžãªçŽ°èæ»ãæå¶ããããšã«ãã£ãŠæ²»çå¹æãéæããããšã㧠ããã ãããã¯ãçŸæ£ã®åå ãšãªã£ãŠããç¥çµçŽ°èã®ç°åžžãªååãå¢æ®ãæå¶ãã ããšã«ããã æ²»çå¹æãéæããããšãã§ããã
éã«ãæ¬çºæã«ãã£ãŠåŸãããšãã§ãããã¢ããäžã·ã¹ãèªå°ãã掻æ§ã䞊ã³ã« ç¥çµçŽ°èã®ååãããã¯å¢æ®ãèªå°ãã掻æ§ãä¿é² (up regulation)ããã£ååç©ã¯ã çŸç
ã®åå ãšãªã£ãŠããç°åžžãªçŽ°èæ»ãæå¶ããããšã«ãã£ãŠæ²»çå¹æãéæã ãããšãã§ããã ãããã¯ãçŸæ£ã®åå ãšãªã£ãŠããç¥çµçŽ°èã®ç°åžžãªååãå¢æ® ãæå¶ããããšã«ããã æ²»çå¹æãéæããããšãã§ããã